

COPY
203605
19619

1 IN THE UNITED STATES DISTRICT COURT
2 FOR THE WESTERN DISTRICT OF TENNESSEE
3 EASTERN DIVISION
4

5
6 WOODROW STERLING, et al,)

7 Plaintiffs,)

8 vs.)

NO. 78-1100

9 VELSICOL CHEMICAL)
10 CORPORATION,)

11 Defendant.
12

13
14
15 TRANSCRIPT OF THE EVIDENCE

16 VOLUME LVIII

17 SEPTEMBER 20, 1983
18
19
20
21
22
23
24
25

DEC 20 '87

I N D E X

WITNESS	DIRECT	CROSS	R/D	R/C
Raymond D. Harbison	8693	8752	8793 8821	8816
<i>Separate binder?</i> Caroleen Scott Clark	8830			

E X H I B I T S

<u>NUMBER</u>	<u>IDENTIFICATION</u>	<u>EVIDENCE</u>
---------------	-----------------------	-----------------

497	8747	8750
499	8756	8756
500	8758	8758
501	8762	8762
502	8763	8763
503	8764	8764
504	8778	8783
505	8786	8790
506	8812	
507		8825
276		8828
508	8861	

TUESDAY MORNINGSEPTEMBER 20, 1983

The trial of this case resumed on this date, Tuesday, September 20, 1983, at 9:40 o'clock a.m., when and where evidence was introduced and proceedings had as follows:

THE COURT: I have said good morning, everybody, so long, and it is in the record so many times, that I am just going to say good morning.

THE LAWYERS: Good morning.

THE COURT: All right, Mr. Gentry.

MR. GENTRY: Thank you, Your Honor.

This morning we have a witness who was on briefly before the Court in January. He has been sworn. I will call him to the stand. Dr. Harbison.

- - - - -

9.20.83
RAYMOND D. HARBISON,

having been previously sworn, was examined and testified further as follows:

DIRECT EXAMINATION
BY MR. GENTRY:

MR. GENTRY: If the Court please, we will voir dire Dr. Harbison on other areas of expertise other than that which he was qualified in January, which was toxicology.

THE COURT: All right, sir.

MR. GENTRY: He is also, we believe, an expert in other areas. I would proffer his previous CV to the Court.

Q. Dr. Harbison, it has been quite some time since you were on the stand before. Tell us your full name, if you will, please, and where you live?

A. My name is Raymond D. Harbison, and I live in Little Rock.

Q. We have previously established that one of your disciplines is toxicology. Tell us a little bit about that. Where are you as a toxicologist?

A. I am the Director of the Division of Inner-Disciplinary Toxicology at the University of Arkansas School for the Medical Sciences, and I am in the Inner-

1 Disciplinary Toxicology Program between the medical
2 science campus and the National Center for Toxicology
3 Research.

4 Q. What is the National Center for Toxicological
5 Research?

6 A. The National Center is a Congressionally
7 mandated facility, which was established approximately
8 ten years ago, and the purpose of the National Center
9 is to conduct mission oriented research in the area
10 of toxicology to resolve or solve national problems
11 that arise regarding chemicals, drugs and other sub-
12 stances.

13 Q. Tell me how that works as a practical matter?
14 Tell me what questions you are asked, where are you
15 asked, where the questions come from, who generates
16 the questions?

17 A. The questions can be generated by Congress, by
18 the National Institutes of Health, by the National
19 Toxicology Program, and the questions that would be
20 asked are is the substance a cancer-causing agent, or
21 might it have a potential for causing birth defects,
22 or might it be a mutagenic material or what the inherent
23 toxicological properties of the material might be.

24 Q. Are the national laboratories to which you are
25 referring and the laboratories of the University of

1 Arkansas School of Toxicology the same laboratories?

2 A. Well, they are physically separated, and, no,
3 they are not the same laboratories. They are
4 different.

5 Q. You wear two hats then?

6 A. That is correct.

7 Q. Let's talk in terms of the University School
8 of Toxicology first. What kind of programs do you
9 have at that particular school?

10 A. The toxicology program at the University
11 serves several functions. One of our missions is
12 education. We have a graduate training program in
13 which we have about fifteen to twenty students who
14 are seeking degrees in toxicology.

15 Q. Are those doctoral degrees or something less
16 than that?

17 A. They would be a person seeking a doctoral
18 degree.

19 We also serve the educational function of
20 training physicians in the area of toxicology, and we
21 also serve as a consulting function for the personnel
22 of the medical center in cases where there might be
23 suspicion of poisoning or unusual incidences in which
24 there might be some need to have extra information
25 or a resource to help treat these patients.

1 Q. This is at the University as opposed to the
2 National Laboratory?

3 A. That is correct.

4 Q. Do you serve the EPA at the University?

5 A. Yes, I do.

6 Q. In what manner?

7 A. At the University I run a medical monitoring
8 program for the United States Environmental Protection
9 Agency, and I also provide a technical toxicological
10 report service for the agency, for its contractors
11 who are involved nationally in the investigation of
12 hazardous waste sites, and the way it works is
13 that we perform pre-employment examinations on the
14 hazardous waste site workers. We also do an annual
15 surveillance of hazardous waste site workers, and we
16 provide toxicological information when it is needed
17 for the investigation of the sites or for any problems
18 that might arise regarding chemical contamination of
19 personnel who are involved in waste site investigations.

20 Q. As head of the School of Toxicology at the
21 University of Arkansas Medical School, do you or do
22 you not teach med students?

23 A. Yes, I do teach medical students.

24 Q. What do you teach them?

25 A. I teach them the basic principles and concepts

1 of toxicology. I teach them about chemicals and the
2 effects that chemicals can have and generally prepare
3 them for the diagnosis, treatment and management of
4 any chemicals which might induce some ailment.

5 Q. I want to digress one minute. You have already
6 testified to this, but briefly give us your educational
7 background?

8 A. I received a Doctorate in Toxicology at the
9 University of Iowa in 1969. Prior to that, in 1965
10 I received a Bachelor of Science Degree in Pharmacy
11 from Drake University. I subsequently was hired by
12 Tulane Medical School, where I was on the faculty
13 from 1969 until 1971, and in 1971 I went to Vanderbilt
14 Medical Center, where I was in the Division of
15 Clinical Pharmacology and Toxicology until approximately
16 1981, when I was recruited to the University of
17 Arkansas for Medical Sciences.

18 Q. What is the discipline pharmacology?

19 A. Pharmacology is one of the basic sciences
20 of medicine, and pharmacology is a study of the
21 effects of drugs, the design and development of drugs
22 and the testing of drugs for their efficacy in the
23 treatment of diseases.

24 Q. Is your Ph.D. both in pharmacology and
25 toxicology?

1 A. Yes, it is.

2 Q. Are you a registered pharmacist?

3 A. Yes, I am.

4 Q. Have you taught pharmacology before?

5 A. Yes. I have taught pharmacology for the past
6 decade at Tulane Medical School as well as Vanderbilt.

7 Q. If one is a pharmacologist, does one need to
8 know how the body metabolizes various drugs?

9 A. Yes. It's essential that one does that,
10 because the length of action and the effects that
11 drugs have on the body are generally dependant upon
12 their metabolism.

13 Q. What is a teratologist?

14 A. A teratologist is one who studies the
15 production of birth defects or studies of the causes
16 of birth defects.

17 Q. What experience do you have in the field
18 of teratology?

19 A. Well, the thesis that I prepared for my
20 doctoral degree was in the area of teratology, and
21 I described the geratogenics of the anticonvulsant
22 Diphenylhydantoin, and generally described
23 the effects that this drug had on the developing
24 embryo and fetus. Since that time, I have been
25 funded for approximately the past twelve years by the

1 National Institute of Health to look at the effects of
2 chemicals and environment pollutants on perinatal
3 development, which is the development that occurs
4 before birth and shortly thereafter.

5 Q. Just as a ballpark figure, how many funds
6 have you received from the National Institute of
7 Health?

8 A. A dollar amount?

9 Q. No, numbers.

10 A. Numbers of grants?

11 Q. Yes.

12 A. I would estimate somewhere around a dozen.

13 Q. What is the National Institute of Health?

14 A. The National Institute of Health -- the
15 National Institutes of Health -- there is more than
16 one Institute of Health -- are those institutes which
17 are part of the United States Public Health Service
18 whose mission it is to describe and to research
19 various diseases and causes of diseases and to report
20 on those causes and develop cures for those diseases
21 and treatments.

22 Q. Are you also an editor of a paper or magazine
23 that deals with teratology?

24 A. Yes. We call it a journal rather than a magazine--
25 but, yes, I am.

1 Q. How often does it come out?

2 A. I believe it is published about every two
3 to three months.

4 Q. And what is the name of that journal?

5 A. The name of the journal is Teratogenesis,
6 Mutagenesis and Carcinogenesis.

7 Q. How long have you been editor of that journal?

8 A. I am not the specific editor, but I am on the
9 editorial board -- for about the past three or four
10 years.

11 Q. Is that a fairly widely distributed journal?

12 A. Yes, it is.

13 Q. Are you a writer?

14 A. Yes, I am.

15 Q. Tell me what you produce as far as writing
16 is concerned?

17 A. Well, I have written approximately 85 to
18 a hundred papers, chapters in books, during the past
19 ten or twelve years. They have been all in the field
20 of toxicology and pharmacology and some of those
21 have been specifically in the subspecialty of
22 teratology. That would be what I have done in the
23 past ten or twelve years.

24 Q. You recently put into evidence your CV. It's
25 an Exhibit. I think it is Exhibit 352. Are some

1 of your publications contained in that particular
2 exhibit?

3 A. Yes, they are.

4 Q. I see a total of 69. Would that be approximately
5 correct?

6 A. Well, those may have been the ones I put in
7 some two years ago. However, it has changed since
8 then.

9 Q. You have added to that number?

10 A. That's correct.

11 Q. Are you an advisor of any degree to anybody
12 regarding toxicology, pharmacology and/or teratology?

13 A. Yes, I am.

14 Q. Tell me what type of advising you do?

15 A. I have been an advisor to the National Institutes
16 of Health for approximately the last eight years, nine
17 years, and most recently I have been appointed by
18 the Assistant Surgeon General to advise the National
19 Institute of Occupational Safety and Health on matters
20 of workers' safety, and specifically we meet about
21 four times a year, and when we meet, we review grants,
22 proposals, contracts that have been submitted to the
23 National Institute of Occupational Safety and Health
24 for the study of the cancer-causing effects or the birth
25 defects or mutagenic effects of chemicals that might

1 be found in the workplace. I have also been an
2 advisor to the National Academy of Science on a
3 variety of issues, and those would be the main
4 classes.

5 Q. Are you engaged in any research either at the
6 University laboratories or at the National Laboratories
7 at the present time?

8 A. Yes, I am.

9 Q. Briefly describe those research projects,
10 if you will, please.

11 A. I am involved in research and have research
12 programs at both places. The research that is being
13 conducted at the University of Arkansas for Medical
14 Sciences is supported by the National Institutes of
15 Health, and its main objective is to determine the
16 effect of chemicals on the growth and development of
17 the fetus, and it is also to determine the mechanisms
18 whereby chemicals cause liver disease and diseases
19 of other organs. The research that is being conducted
20 at the National Center of Toxicological Research
21 is focused again on those two areas, looking at the
22 mechanisms whereby chemicals produce liver disease,
23 alter liver function, and also the mechanism by which
24 certain chemicals are able to affect reproduction.

25 Q. Have you written on the effects of chemicals

1 on the liver?

2 A. Yes, I have.

3 Q. How many papers have you published with regard
4 to that particular area of toxicology?

5 A. I would have to estimate it. I think it is
6 around ten to twelve, maybe even more.

7 Q. Are these projects ongoing?

8 A. Yes, they are.

9 Q. Do they involve animal studies?

10 A. Yes, they do.

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 Q Are you a hands-on person when it comes to
2 animal studies?

3 A Yes, I participate daily in the animal
4 experiments at both laboratories.

5 Q What is risk assessment?

6 A Risk assessment is the procedure of making a
7 projection or forecasting the likelihood or the
8 probability that some adverse effect may occur as a
9 result of exposure to some substance.

10 Q Is that a tool of trade to the toxicologist?

11 A Yes, it is.

12 Q Is the pharmacologist involved in that particular
13 tool as well?

14 A The pharmacologists have an important part
15 in that because the basic underlying principles of risk
16 assessment must rely upon certain aspects of the
17 absorption, metabolism, the excretion of chemicals,
18 so that conceptually, yes, risk assessment relies on
19 pharmacology.

20 Q Have you done any risk assessment?

21 A Yes, I have.

22 Q For whom?

23 A I have conducted risk assessments for the
24 United States Environmental Protection Agency, the
25 United States Department of Justice, and for industry.

1 Q Are you teaching any group or organization
2 regarding risk assessments at the present time?

3 A Yes, I am.

4 Q What organization would that be?

5 A I have a contract through the United States
6 Environmental Protection Agency to provide basic
7 risk assessment teaching to the eight southeastern
8 states and also to the U.S. EPA in Region IV, which
9 is in Atlanta, and what we are doing is providing
10 a basic introductory course to state agencies,
11 the Department of Health, the Water Quality Divisions,
12 the Department of Pollution Control and Ecology.
13 We have already conducted one such course here in
14 Tennessee and it is designed to provide a foundation
15 for these people and to introduce them to the
16 principles and concepts of risk assessment so that they
17 are better able to make public health decisions when
18 water supplies or air supplies or ground are
19 contaminated with chemicals.

20 Q Where are you going from here, sir?

21 A I am going to Atlanta, Georgia.

22 Q For what purpose?

23 A We are going to present the course to the EPA
24 and to the State Department of Health for the State of
25 Georgia.

1 Q Do you -- have you put together a textbook
2 for risk assessment?

3 A Yes, I have.

4 Q Is that a textbook that will be used by members
5 of the EPA in these upcoming classes?

6 A Yes, it will.

7 Q What is the -- what is a mutagen?

8 A A mutagen is a substance that is able to
9 interact with the genetic material of a cell and cause
10 a change in that genetic material to generally
11 influence the future development of that cell. The
12 cell can be one which is in the body or the cell
13 could be an egg or a spermatozoa.

14 Q Have you published regarding mutagenicity of
15 compounds and the like?

16 A Yes, I have.

17 Q How many publications?

18 A Again I would have to estimate maybe a half
19 a dozen.

20 Q Now, that journal to which you referred is
21 the journal of what?

22 A Teratogenesis, Mutagenesis and Carcinogenesis.

23 Q Have you published in the area of carcinogenesis?

24 A I have published in the area regarding tumor
25 growth and the treatment of certain types of tumors,

1 solid tumors as well as leukemia. The answer would
2 be yes.

3 Q Have you done risk assessments as far as
4 carcinogens are concerned?

5 A Yes, I have.

6 Q We've discussed pharmacology. We've discussed
7 teratology. You are a toxicologist, but I don't
8 think we have really given a true definition as to
9 what a toxicologist is. Would you give me one,
10 please?

11 A I will try. A toxicologist is one who studies
12 the adverse effects of chemicals and other substances
13 on the living systems.

14 Q Historically when did this science come into
15 fruition?

16 A The origin of the science of toxicology
17 is in the discipline of pathology, although within the
18 modern medical community within the United States
19 toxicology has really evolved out of the basic
20 discipline of pharmacology, and all of the original
21 toxicology training programs were essentially part of
22 the departments of pharmacology.

23 Q When was the first professional society of
24 toxicology established?

25 A The first professional society was established
I believe in 1961. 1960 or '61.

1 Q A fairly new discipline as it relates to the
2 society itself?

3 A That is correct.

4 Q Have the principles and concepts of toxicology
5 changed substantially or none at all over the last
6 ten years?

7 A The principles and concepts have changed.
8 They have evolved over the past ten years and most
9 recently there have been significant changes in those
10 principles and concepts.

11 Q Can you tell me what they are?

12 A Well, specifically in the area of cancer
13 causation. In the past the design of experimental
14 studies^{to}/determine whether or not chemicals cause
15 cancer was simply a mission to use the highest
16 tolerated dose that would produce tumors in animals
17 to simply determine whether it would or would not
18 produce tumors. It has become general knowledge
19 that the mechanism by which chemicals produce tumors
20 is critically important in making safety assessments
21 and trying to develop public policy, and it has been
22 determined that certain classes of compounds produce
23 cancer only when they produce damage to the tissue
24 and they produce it recurrently throughout the lifetime,
25 and so that there has been the evolution of new

1 concepts regarding cancer causation and the factors
2 that are important in that causation.

3 Q What professional societies do you belong to,
4 sir?

5 A I belong to the Society of Toxicology,
6 to the Teratology Society, to the American Association
7 for the Advancement of Science, to the American
8 Society for Pharmacology and Experimental Therapeutics.

9 Q What is an experimental therapeutic?

10 A Experimental therapeutics is the design,
11 development and testing of new drugs for their efficacy
12 or their ability to cure diseases.

13 Q Any other? National Academy of Science, did you
14 name that?

15 A No. I am not a member of the National
16 Academy of Science. I have served as an advisor,
17 but I am not a member of the National Academy.

18 Q How about the New York Academy of Sciences?

19 A Yes, I am a member of the New York Academy of
20 Sciences.

21 Q Have you received any awards in the area of
22 toxicology since you have been in the discipline?

23 A Yes, I have.

24 Q What was that?

25 A In 1978 I received the achievement award from the

1 Society of Toxicology, which is that award given to
2 a scientist under the age of thirty-six who last made
3 a significant contribution to the science. It's
4 given to only one person annually and it's not actually
5 given annually, but some years there have been no
6 awards given.

7 Q While you were in the state of Tennessee did you
8 belong to any state boards that dealt with medicine
9 or toxicology or pharmacology or the like?

10 A I didn't belong to any state boards, but I did
11 have the occasion to be an advisor to the Medical
12 Examiner's Board of the State of Tennessee.

13 Q In what capacity?

14 A I served the attorney's -- the Attorney General's
15 office in advising the Medical Examiner's Board on the
16 usual course of medical practice as it relates to the
17 use of drugs, the pharmacological aspects of it,
18 in reviewing licensure of in reviewing the revoking
19 of licenses of practitioners in the State of Tennessee.

20 Q Do you have at the School of Pharmacology in
21 Little Rock a procedure whereby medical doctors can
22 call you and determine the toxicity of various
23 compounds and chemicals?

24 A Yes, we do.

25 Q Tell me about that, sir, and tell me how it's

1 used.

2 A Well, we have a service which is used by the
3 practitioners at the University Hospital in which
4 we are available to them 24 hours a day, 7 days a week
5 to provide consultation regarding the effects that
6 might be expected or the diagnosis of chemical
7 injury, and that service is also provided to the
8 U.S. EPA contractors on a national basis, so that
9 we essentially are available to all ten regions of
10 the U.S. EPA throughout the United States.

11 MR. GENTRY: Your Honor, at this point
12 of time I would represent to the Court,
13 although the Court's memory is better than
14 mine, that Dr. Harbison has previously
15 been accepted by the Court as a toxicologist,
16 an expert in toxicology. We would also present
17 him to the Court now as an expert also in
18 pharmacology, teratology, and risk assessment
19 as it relates to chemicals and drugs.

20 THE COURT: Is there any objection?

21 MR. GILREATH: No, Your Honor.

22 THE COURT: All right, sir.

23 BY MR. GENTRY:

24 Q Dr. Harbison, let's go back to the research
25 which you described for the Court just a few minutes

1 ago as relates to the liver. Can you give me a
2 mundane description of what your people have been
3 doing as it relates to the various programs you have
4 been carrying out?

5 A Well, we have been trying to determine the ways
6 in which chemicals affect the liver and specifically
7 we have been interested in narcotics and analgesics,
8 that is compounds that are able to affect pain,
9 and we have been interested in the effects that these
10 analgesics have on some of the enzymes that are
11 produced in the liver, specifically the SGPT and SGOT.

12 Q Let me stop you right there. We've had a lot
13 of discussion about liver function tests and I notice
14 you refer to enzymes. Tell me the difference,
15 if you will, please.

16 A Well, SGPT, serum glutamic pyruvic transaminase,
17 and the SGOT, which is a similar enzyme, are enzymes
18 that are produced or synthesized in the liver. They
19 are normally released from the liver and various
20 changes in the liver can alter the level of these
21 enzymes that you would find in blood. And SGPT and
22 an SGOT is not a liver function test. It is an
23 enzyme or it is a set of enzymes that are found in
24 the plasma or in the blood which are made by the
25 liver and they can be altered or changed or elevated

1 depending on how the liver is acting at a particular
2 moment in time.

3 Q Is this an animal study that you have been
4 carrying on or a number of animal studies?

5 A We are carrying on animal studies and we have
6 also conducted human studies.

7 Q As it relates to the liver enzymes?

8 A That is correct.

9 Q Tell me what you have done, if you will,
10 please. I think this is pretty important.

11 A What we have done so far is we have found that
12 drugs like analgesics, including the over-the-counter
13 analgesic acetaminophen or Tylenol, are able to change
14 these enzymes within the blood and can increase
15 the levels of those enzymes within the blood,
16 so that the administration of certain analgesics can
17 cause a significant elevation in SGPT or SGOT levels.

18 Q Is that long lasting?

19 A It is not long lasting. It will generally
20 be a trenchant effect. We have also found that other
21 drug substances which are able to alter the metabolism
22 of the liver, such things as the sedative hypnotics like
23 phenobarbital, the anticonvulsants like
24 diphenylhydantoin, are also able to increase these
25 enzymes in the blood because they have a nonspecific

1 effect of increasing the synthesis of enzymes throughout
2 the liver and as a result of that effect cause an
3 outpouring of these into the bloodstream.

4 Q Is the increase of enzymes into the bloodstream
5 by the introduction of these analgesics into the body,
6 is that indicative of liver damage?

7 A No, it is not.

8 Q What is it indicative of?

9 A Well, it is indicative of a change within
10 the liver whereby these compounds and others can
11 cause an increase in the synthesis of these enzymes
12 and thereby the increase in the production or the
13 synthesis of the enzymes causes an increase of these
14 in the bloodstream, so it's a simple physiological
15 response.

Q. In these experiments or tests, what have you, do you have reason to look at liver slides?

A. Yes, I do.

Q. How often?

A. Oh, certainly on a weekly basis, probably every couple of days.

Q. And for what purpose?

A. For the purpose of determining whether or not there is a cell death that has occurred or what other changes might have occurred within the liver, which might have led to the elevation in the enzymes or the other effects that we may have seen.

Q. Now, you used a word that has puzzled me throughout this litigation. We are talking about the liver now, and you refer to cell death. Is it possible to have damage to the liver without having cell death?

A. Yes, it is.

Q. Let me ask you if you have, say, ten or eleven drinks one evening, would that create liver damage?

A. Yes, it would.

Q. Under ordinary circumstances with an ordinary human being, would it create cell death?

A. No, it would not likely create cell death or cause cell death.

2-2 1 Q. Explain to me the difference between damage
2 and cell death, if you can?

3 A. Well, in damage there is a change in the
4 cells of the liver, for example, in which these cells
5 may become leaky, that is, they cause a discharge or
6 a leaking of the enzymes into the bloodstream. The
7 cell death is where the cell is actually destroyed, and
8 it needs to be replaced, and the cells of the liver
9 are quite easily replaced. So that in the case of
10 cell death, there will not be any sort of survival
11 or any rebounding of that particular cell. It's dead.

12 Q. Is the liver a sensitive organ or resilient
13 organ?

14 A. The liver is a resilient organ.

15 Q. What is its purpose and function?

16 A. The purpose of the liver is to clean the blood
17 of substances that are normally produced by the body,
18 such as steroids, the breakdown products of blood;
19 for example, bilirubin. It also has a function to
20 synthesize or to produce other substances like clotting
21 factors, steroids and other materials that it produces
22 or alters by metabolizing them. So it has two
23 functions, really. One is to cleanse the blood,
24 to serve as an excretory organ, and the other is
25 to synthesize materials that are essential for life.

3-3

1 Q. What is necrosis?

2 A. Necrosis is cell death which can be seen on
3 observation of the liver.

4 Q. In your experiments, to which you have been
5 referring, do you sometimes see necrosis on your
6 liver slides?

7 A Yes, we do.

8 Q. The liver damage, which you just described
9 earlier, not the cell death, but the liver damage,
10 can you see it on your slides?

11 A. Oftentimes you will not be able to see liver
12 damage.

13 Q. It depends on the range of the damage?

14 A. That is correct.

15 Q. Are you familiar with the compounds carbon
16 tetrachloride and chloroform?

17 A. Yes, I am.

18 Q. And in what manner?

19 A. Well, I have generally known about them for
20 the past decade or more. While I was in pharmacy
21 school, I had the occasion to prepare compounds that
22 contained chloroform and dosages of medication for
23 worms containing carbon tetrachloride. I have
24 generally throughout my education experience been exposed
25 to basic research that has been conducted on carbon

1-4

1 tetrachloride and chloroform. I have done basic
2 research on carbon tetrachloride and chloroform and
3 have an active research program at this point on
4 carbon tetrachloride and chloroform.

5 Q. Well, I would like to explore that, but first,
6 let me ask you this: Have carbon tetrachloride and
7 chloroform been used as analgesics in the past?

8 Q. As analgesics?

9 Q. Yes.

10 A. Actually, yes, they have. Carbon tetrachloride
11 specifically -- carbon tetrachloride has been used
12 as a topical treatment for burn injuries approximately
13 twenty years ago.

14 Q. Have they been used as drugs in the past?

15 A. Yes, they have.

16 Q. In what manner?

17 A. Well, carbon tetrachloride has been used
18 quite extensively in the treatment of worms. Carbon
19 tetrachloride in the southeastern part of the United
20 States was extensively used, and actually was in the
21 textbooks of pharmacology when I was taking pharmacology.
22 There are reports of the successful treatment of more than
23 a hundred and twenty thousand patients with carbon
24 tetrachloride. Chloroform has also been used as a
25 drug. It has been used as an anesthetic. It has also

3-5

1 been used as a preservative, and it has been used as
2 a carminative or a flavoring agent in the solution
3 of other drugs and substances which don't taste
4 very good.

5 Q. Before we get to your research program on
6 carbon tetrachloride, tell me about that study with
7 20,000 people. What type of study was it?

8 A. The study of 20,000 people was a study in
9 which the outcome of the treatment of patients who
10 had tapeworms was conducted; that is the patients
11 were followed, and it was an observation of the adverse
12 effects that occurred as a result of the use of carbon
13 tetrachloride or the lack of those effects.

14 Q. What type of doses were given to those people?

15 A. The general recommended dose was approximately
16 five grams for an adult, given as a single dose,
17 followed in approximately two weeks by another dose
18 if the worms were not passed within that period of
19 time.

20 Q. What dose would that be, the second dose?

21 A. The second dose would have been the same,
22 approximately five grams for an adult person.

23 Q. Ten grams in two weeks?

24 A. That's correct.

25 Q. Tell me about your research program as it relates

1 to carbon tetrachloride?

2 A. The research program that we are conducting
3 is one to describe the inter-action between carbon
4 tetrachloride and chloroform in other chemicals,
5 and we have defined the ability of carbon tetrachloride
6 and chloroform to produce liver damage, and the ability
7 of other chemicals to increase that ability to produce
8 damage, and our general objective is to describe
9 the synergistic activities, if you will, between
10 carbon tetrachloride, chloroform and other chemicals.

11 Q. Let me refer you to Exhibit 18. Are you
12 familiar with that exhibit?

13 A. Yes, I am.

14 Q. As a result of the experiments that you have
15 been doing with carbon tetrachloride and chloroform,
16 can you tell me and the court what the synergistic
17 effects of all those chemicals there would be with
18 carbon tetrachloride and chloroform?

19 A. I don't believe there would be any synergistic
20 effects between those compounds listed on there with
21 carbon tetrachloride and chloroform. Our research,
22 as well as that of others, has really described
23 two chemical classes that caused synergistic effects
24 between carbon tetrachloride and chloroform, and those
25 two chemical classes are alcohol or various alcohols,

1 and ketones, and those are really the only two classes
2 that have been described which cause a synergistic
3 effect between carbon tetrachloride and chloroform.

4 THE COURT: Ask him to describe what
5 he means by synergistic effect.

6 MR. GENTRY: Certainly, Your Honor.

7 Q. Would you describe what you mean by that?

8 A. Yes. Synergism is the effect whereby when
9 two chemicals are given or one is exposed to two
10 chemicals, there is more than an additive effect. You
11 don't simply add up the effects of one versus the
12 other, but when the two are administered together,
13 there is a greater than an additive effect.

14 THE COURT: The witnesses here have
15 used the word potentiation. Would that be
16 pretty much in the same class of what you
17 are talking about -- maybe producing a more
18 powerful effect possibly?

19 THE WITNESS: It's not a more powerful
20 effect. The term potentiation has very
21 specific meaning. Potentiation is a term
22 that is used when you give one compound that
23 has no effect itself. It has no intrinsic
24 or inherent toxicological properties. But it
25 greatly exaggerates the toxicity seen by another

2-8

1 compound. So rather than seeing the
2 effect that you would expect at this particular
3 dose level, if you give the two together
4 now, you would see considerably more than
5 you would have expected.

6 THE COURT: So there is a difference
7 between the two concepts?

8 THE WITNESS: Yes, sir, there is.

9 Q. (By Mr. Gentry) Well, let's talk about potentia-
10 tion as it relates to these compounds on Exhibit 18.

11 Can you give me an opinion if there is a
12 potentiation between carbon tetrachloride and/or
13 chloroform and the other compounds?

14 A. The same would apply; that the potentiation
15 and the synergism that occurs is confined to two
16 distinct chemical classes, and those are alcohols
17 and those are ketones. There aren't any alcohols
18 or ketones on that list.

19 Q. What is a metabolite?

20 A. A metabolite is a product that is produced from
21 a chemical or a drug that would be ingested in man or
22 that would be given to an animal. It is a changed
23 material.

24 Q. Are metabolites important in your research
25 as it relates to carbon tetrachloride and chloroform?

9 1 A. Yes, sir, they are critically important.

2 Q. Tell me why?

3 A. Because carbon tetrachloride and chloroform
4 themselves do not produce liver injury. It is only
5 the metabolites of carbon tetrachloride and chloroform
6 that produce the injury. The carbon tetrachloride
7 and chloroform themselves are rather stable molecules,
8 and until you extract a chlorine from the molecule
9 it does not become biologically important or reactive
10 within the liver system or within other organs of the
11 body.

12 Q. Are there some chemicals, compounds, or drugs
13 that will produce more metabolites than others?

14 A. That will result in the production of more
15 metabolites for themselves?

16 Q. Yes.

17 A. Yes, there are.

18 Q. Where do you classify carbon tetrachloride
19 and chloroform?

20 A. Their metabolism is fairly simple, and they
21 do not produce a lot of metabolites.

22 Q. Is that important to your study?

23 A. Yes, it is.

24 Q. Tell me why?

25 A. Well, because in trying to determine the

10 1 mechanism by which a drug or chemical produces an
2 effect, it is important to know what the metabolites
3 are, because in most all instances in which there is
4 liver damage, the liver damage is produced by a
5 metabolite. It is not produced by a parent compounded
6 cell. In the case of carbon tetrachloride and chloroform,
7 there are really very few metabolites produced; so it
8 is a much easier task to identify what the causative
9 agent is than, for example, in one in which you might
10 have fifty metabolites or considerably more.

11 Q. Have you reached any conclusions as a result
12 of your studies of carbon tetrachloride and chloroform
13 in the laboratories?

14 A. Yes.

15 Q. Synergistically and the like?

16 A. Yes.

17 Q. What are the conclusions?

18 A. Well, the conclusions are that in order to
19 increase the toxicity of carbon tetrachloride and
20 chloroform as seen in the liver, that is to be able
21 to produce the necrosis or cell death, it is essential
22 that the compounds be given for a period of time which
23 will allow synthesis of new enzymes to increase the
24 ability of the liver to be able to convert the carbon
25 tetrachloride and chloroform to the more toxic species

3-11

1 and the more proximate cause of the injury.

2 Q. Can you say that in a little simpler terms?

3 A. Well, it's essential that the compound changed
4 the metabolism of the liver in order to create a
5 liver which is now different such that it handles
6 carbon tetrachloride and chloroform in a different
7 manner than it did before.

8 Q. Now, is that change damage or cell death?

9 A. The change that we see with the carbon
10 tetrachloride and chloroform?

11 Q. Yes.

12 A. We are looking at both damage as well as
13 cell death.

14 Q. Is there -- excuse me. Have you finished?

15 A. We look at both.

16 Q. Is there a threshold of the amount of carbon
17 tetrachloride and chloroform that you give the
18 animal over which there is cell death and under which
19 there is damage?

20 A. Yes.

21 Q. You have read a number of parts of the
22 transcript of this trial, have you not?

23 A. Yes, I have.

24 Q. And you have attended certain days of this
25 trial as well, have you not?

1 A. Yes, I have.

2 Q. Are you familiar with Dr. Rodricks and his
3 testimony?

4 A. Yes, I am familiar with his testimony, yes,
5 I am.

6 Q. Are you familiar with his calculations?

7 A. Yes, I am.

8 Q. Are you familiar with the word or words that
9 he used on Exhibit 237 -- "cumulative exposure."

10 A. Yes, I am.

11 Q. What did he mean by that, Doctor?

12 A. Well, by cumulative exposure he added up the
13 levels that the individuals would have been exposed
14 to over a period of time and took that cumulative
15 amount to be the amount that the individual would
16 have been exposed to and thereby would have had in his
17 system to produce the effects which he says would
18 occur.

19 Q. Was Dr. Rodricks a pharmacologist?

20 A. I don't believe so. I think he testified
21 that he was a chemist or a biochemist.

22 Q. As a pharmacologist, and we are talking
23 specifically about carbon tetrachloride and chloroform,
24 as a pharmacologist, does the cumulative exposure
25 make sense as far as human beings are concerned?

1 A. No, sir, it does not.

2 Q. What happens to carbon tetrachloride and
3 chloroform -- and/or chloroform when the human
4 body either ingests it or inhales it?

5 A. Carbon tetrachloride and chloroform are
6 readily excreted. Carbon tetrachloride and chloroform
7 are blown off in the expired air. They are also
8 rapidly converted to metabolites and rapidly excreted
9 following that conversion. So they do not stay
10 around for a long period of time.

11 Q. When you say rapidly excreted, are you talking
12 in terms of hours, days or months?

13 A. I am talking in periods generally of days.
14 It certainly would not be months, but it probably
15 would be days.

16 end
17
18
19
20
21
22
23
24
25

1 Q When you ingest carbon tetrachloride and/or
2 chloroform where does it go?

3 A When you ingest it most of it will go immediately
4 to the liver. The vessels in the intestine, which
5 are called the greater omental vessels, are those
6 which collect the material from the intestine and will
7 generally go directly to the liver, and chloroform
8 and carbon tetrachloride are compounds which generally
9 on the first pass through the liver will be
10 sequestered by the liver, so they are very efficiently
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

1 taken up by the liver, so very little would get out
2 into the rest of the system in circulation following
3 the oral ingestion of those materials.

4 Q When you inhale carbon tetrachloride and chloroform
5 what happens to them?

6 A When you inhale carbon tetrachloride and
7 chloroform it would be likely that they would get
8 into the systemic circulation much more efficiently,
9 that is to the brain and to other organs of the body,
10 before they get to the liver, because the blood
11 would go to other organs first.

12 Q In light of the characteristics of carbon
13 tetrachloride as those characteristics relate to the
14 metabolizing by the body of the compounds, is daily
15 dosage more important than cumulative exposure?

16 A Yes, it is.

17 Q At the risk of being repetitious, explain to
18 me again why.

19 A Well, the daily dosage is important because
20 that is the dosage which will determine whether or
21 not the level of chemical reaches a level that is
22 able to produce some response in the body, and unless
23 it's able to reach that level on a daily basis it
24 will not produce any effect.

25 Q I'm going to slip sideways on the direction

4-3

1 of this examination if you will allow me, sir,
2 and ask you if there's a book called Clinical
3 Toxicology of Commercial Products?

4 A Yes, there is.

5 Q What's the purpose of that book?

6 A The purpose of that book is to identify the
7 constituents that are contained within commercial
8 products for the purpose of treatment and diagnosis
9 of persons who might have unintentionally or
10 intentionally ingested those products. You will find
11 that text in most poison control centers and in most
12 emergency rooms, because it is a quick reference
13 to allow one to determine the makeup of some material
14 that someone may have ingested.

15 Q Is it substantial in size?

16 A Yes, sir; it's probably four to five inches
17 thick. It's quite a large textbook.

18 Q At my request did you extract from that
19 book some information on carbon tetrachloride as it
20 relates to commercial products?

21 A Yes, I did.

22 Q I know it's rather lengthy, but tell us about
23 some of the products, some of the commercial products
24 in which we find carbon tetrachloride presently and
25 then give us an estimation of how many products there

1 are with a not unsubstantial amount of carbon
2 tetrachloride contained therein.

3 A Well, carbon tetrachloride is contained in
4 probably, I would estimate from the list, maybe thirty
5 to fifty products. It is contained in paint removers,
6 it's contained in a variety of carburetor cleaners,
7 it is most extensively used as a pesticide and as a
8 fumigant, and --

9 Q What's a fumigant?

10 A A fumigant is a material that is used as a
11 pesticide, but because it is volatile you are able to
12 put the material within an enclosed space and have it
13 get to essentially all parts of that space because of
14 its volatility and thereby kill off the pest that you
15 don't want in there.

16 Q Do you use that with grains?

17 A With grains?

18 Q Yes.

19 A Yes, sir.

20 Q I notice one of the first brand names is
21 Acritet 34-66 fumigant.

22 A Yes.

23 Q By whom is that made?

24 A It's made by Stauffer Chemical Company.

25 Q There's also a reference to refrigerants. Is

4-5

1 carbon tetrachloride contained in refrigerants?

2 A Yes, it has also been used as a refrigerant.

3 Q How many different companies, approximately,
4 how many different manufacturers, use carbon
5 tetrachloride presently in the manufacture of their
6 various products?

7 A Well, I've not closely counted them. I would
8 say there are probably at least a dozen.

9 Q In that book to which we have previously
10 referred, Clinical Toxicology of Commercial Products,
11 is there a section under carbon tetrachloride dealing
12 with minimum acute toxicity concentrations?

13 A Yes.

14 Q What does that mean?

15 A I'm sorry, let me make sure I understand.

16 Did you say is it in the book or is it in this paper?

17 Q Is it in that?

18 A On this paper?

19 Q Yes.

20 A Yes, it's on the paper.

21 Q Is that not contained in the book?

22 A No, it is not contained in the book.

23 Q Where do you get the minimum acute toxicity
24 concentrations?

25 A The minimum acute toxicity concentrations are

1 those concentrations which are derived from a set
2 of publications that the United States Environmental
3 Protection Agency published some years ago and they
4 are called Multimedia Environmental Goals, and what
5 it allows one to do is to calculate a concentration
6 to which one could be exposed for short periods of
7 time, and that's what the minimum acute toxicity
8 concentration is.

9 Q What is the minimum acute toxicity concentration
10 for carbon tetrachloride in air?

11 A It's ten parts per million.

12 Q In water?

13 A It's nine hundred seventy-five parts per
14 million.

15 Q Parts per what?

16 A Per million.

17 Q Now, I see something, land. Would that be
18 in the dirt or earth or what have you?

19 A That would be soil contaminated or containing
20 carbon tetrachloride.

21 Q And how many -- what's the minimum acute
22 toxicity concentration for that?

23 A That's one thousand nine hundred parts per
24 million.

25 Q Where is that information contained that you

1 just gave me as far as the EPA is concerned? \

2 A It is derived from the Multimedia Environmental
3 Goals, which is a methodology that the EPA proposed
4 for determining concentrations to which people
5 could be exposed for short periods of time as well
6 as long periods of time.

7 Q Has the EPA derived a mathematical formula
8 which translates into permissible concentrations of
9 carbon tetrachloride over a 24-hour a day 7-day a week
10 environmental circumstance?

11 A Yes, it has.

12 Q Can you tell me what that is for air?

13 A The estimated permissible concentration for air,
14 and that is the concentration to which one can be
15 exposed for 24 hours a day 7 days a week, is point
16 zero two parts per million.

17 Q That would be twenty parts per billion?

18 A That's correct.

19 Q All right. What about water?

20 A For water it's two point three one parts per
21 million.

22 Q And that's 24 hours a day 7 days a week?

23 A That is correct.

24 Q For a lifetime?

25 A That is correct.

1 Q And that was parts per million?

2 A Parts per million.

3 Q All right. Land?

4 A Land is four point six two parts per million.

5 Q Doctor, are carbon tetrachloride and chloroform
6 suspected carcinogens?

7 A Yes, they are.

8 Q Tell me how and why they are suspected as
9 carcinogens.

10 A Both carbon tetrachloride and chloroform
11 are suspected carcinogens because in some animal
12 studies it has been found that both of these agents
13 are able to produce tumors, and specifically tumors
14 of the liver.

15 Q Under what circumstances?

16 A Under circumstances of high concentrations
17 over a prolonged period of time and under circumstances
18 in which there is necrosis, cell death, that occurs
19 over a substantial period of the lifetime of the
20 organism, the animal.

21 Q Is chloroform a teratogen?

22 A Chloroform is teratogenic in mice or it has been
23 found to be teratogenic in mice. It is not a
24 human teratogen.

25 Q Is carbon tetrachloride a teratogen?

1 A Carbon tetrachloride is -- there is considerably
2 less evidence even for carbon tetrachloride. It is
3 not a human teratogen.

4 Q Are chloroform and carbon tetrachloride
5 mutagens?

6 A No, they are not.

7 Q Is that important?

8 A Yes, it's extremely important.

9 Q Tell me why?

10 A Well, if carbon tetrachloride and chloroform
11 were mutagenic substances, what that means is that
12 they have the ability to bind to the genetic material,
13 the DNA, and it means that they can cause cancer
14 and that exposure over a period of time resulting
15 in that genetic damage could in fact lead to tumors,
16 but neither carbon tetrachloride or chloroform
17 have been found to be mutagenic, which means
18 essentially that they do not bind to the genetic
19 material and they do not cause cancer by causing a
20 change in the genetic material.

21 Q Were you in the courtroom yesterday when Dr.
22 Sullivan talked in terms of binding?

23 A Yes, I was.

24 Q He described a physical property of these
25 compounds that I think made it difficult for them to

1 bind. Are you familiar with that?

2 A Yes, I am.

3 Q Tell us about it again, if you will, please.

4 A Well, carbon tetrachloride and chloroform,
5 because they contain only a single carbon atom,
6 cannot form intermediates which are able to bind to
7 macromolecules or various molecules within the
8 cell, and more importantly they are not able to bind
9 to DNA to cause some sort of damage or error within
10 that material, so they do not have the chemical
11 makeup to be able to be biotransformed or converted
12 to metabolites which are able to bind.

13 Q Is this important as it relates to the manner
14 in which people view carbon tetrachloride and chloroform
15 when they are talking in terms of carcinogenicity?

16 A Yes, it's very important.

17 Q Tell me why.

18 A Well, again because neither of those two
19 compounds are able to bind to DNA. That means
20 that they will not be able to initiate the process of
21 cancer or cause the process of cancer or that process
22 which leads to cancer, and unlike other substances
23 which are it means that these compounds cannot be those
24 which bind and cause cancer themselves. They must
25 have some other event, either through the process of

1 killing the cells or using massive doses to kill cells
2 that will ultimately lead to the cancer process.

3 Q There are technical names for the type of
4 toxins these are as opposed to the type of toxins
5 that might bind with a cell, are there not, sir?

6 A Yes, sir.

7 Q We have heard them a number of times, haven't
8 we?

9 A Yes, we have.

10 Q Just for the purpose of the record let's voice
11 them again and then forget about them, because I think
12 what you have described is adequate for our purposes.

13 A Okay. Those chemicals which are able to
14 bind to DNA and initiate the process of cancer are
15 called genotoxic chemicals. Those chemicals which
16 are not able to bind to DNA but can under certain
17 circumstances cause cancer because they consistently
18 cause cell death at high levels or massive exposure
19 levels, those compounds are called epigenetic
20 carcinogens.

21 Q And what is carbon tetrachloride and chloroform?

22 A Carbon tetrachloride and chloroform are
23 epigenetic carcinogens.

24 Q Doctor, I'd like for you to, if you have it in
25 front of you, turn to Exhibits 232, 233, 234, 235 and

1 the supplements put into the record by Dr. Rodricks
2 as a result of summary calculations. Do you
3 recognize those?

4 A Yes, I do.

5 Q First, for the purpose of your testimony, tell
6 us what those calculations are, about -- toward whom
7 they are directed, and whether or not there are any
8 footnotes on any of those.

9 A Okay. Exhibit 232 is the estimated chemical
10 doses of selected chlorinated hydrocarbons to S. Sterling,
11 1969 through 1978, and it is an estimated cumulative
12 dose of carbon tetrachloride, chloroform, chlorobenzene
13 and tetrachloroethylene, and also an estimated average
14 daily dose of those same materials from drinking water
15 and from inhalation exposure.

16 Q What's 233?

17 A 233 is essentially the same thing, only this
18 is for D. Johnson and it's 1976 through 1978.

19 Q And 234?

20 A 234 is for the Maness child, and this is April
21 '76 through March '78.

22 Q Now, the next group of papers you have would be
23 Exhibit 237, and what is the difference in those papers
24 and the ones that you have just described?

25 A The next one I have is 235.

1 Q All right. Then you have one that's 237,
2 the footnotes. It's not so marked.

3 A It's not so marked 237, yes, but it has the
4 footnotes which are the --

5 MR. GENTRY: I'm sorry, Your Honor,
6 I'm transposing numbers, which I'm wont to
7 do. It's 327.

8 THE COURT: All right.

9 BY MR. GENTRY:

10 Q Those are the ones with the footnotes that
11 are essentially the same as the previous exhibits
12 except they have footnotes, is that correct, sir?

13 A That is correct.

14 Q Did you have reason to review those recently?

15 A Yes, I have.

16 Q For what purpose?

17 A For deriving the assumptions that Dr. Rodricks
18 used in the calculations of his estimated doses.

19 Q Turning to 327, which is the one with the
20 footnotes, let's look at the daily dosage of carbon
21 tetrachloride and chloroform for Mr. Steve Sterling,
22 both as a result of inhalation and ingestion.

23 Do you see that, sir?

24 A Yes, I do.

25 Q What is the daily dose for chloroform shown in

1 Dr. Rodricks' figures?

2 A The daily dose for chloroform would be point
3 zero two two milligrams per kilogram.

4 Q Which extrapolates out to what, parts per
5 billion?

6 A Well, it would be parts per billion, but that
7 would not be the proper way of using parts per billion.

8 Q Because of the milligram per kilogram?

9 A That's correct.

10 Q Is there any as far as ingestion is concerned
11 for chloroform?

12 A You mean inhalation?

13 Q I mean inhalation.

14 A No, there is nothing for inhalation.

15 Q Now, what is the average daily dose for ingestion,
16 Steve Sterling, shown by Dr. Rodricks in Exhibit 327
17 of Carbon tetrachloride?

18 A For carbon tetrachloride it is point two three
19 milligrams per kilogram.

20 Q And inhalation?

21 A Inhalation is point eleven milligrams per kilogram.

22 Q Now, there's an interesting footnote with
23 regard to the exposures here. Read those footnotes,
24 if you will, please.

25 A The first footnote, number 1, is body weight

1 assumed to be sixty kilograms. Footnote number 2
2 is calculations are based on drinking water consumption
3 through November 1977 and inhalation exposure through
4 March 1978. Footnote number 3 is assumed two liters
5 per day of well water consumed. Average ex -- I'm
6 sorry. Number 4, the footnote number 4, is average
7 exposure for highest year in milligrams per kilogram
8 per day.

9 Q All right. Now, just a second. The average
10 daily exposure to which you have just referred is the
11 highest year?

12 A That's what it says.

13 Q That figure does not take into consideration
14 any other years that were lower than the highest
15 year?

16 A No, it does not.

17 Q Is that footnote the same for Daniel Johnson
18 and for Jimmy Maness?

19 A Yes, it is. The only difference is that
20 on Maness it's footnote number 3 rather than footnote
21 number 4, but it's essentially the same wording.

22 Q Still referring to 327, what did Dr. Rodricks
23 assume in that table as it relates to these daily
24 doses?

25 A He assumed that there would be a consumption

1 of two liters of water a day and he assumed some
2 other things about the amount of time spent within
3 the bathroom in showering, and so forth, for the
4 inhalation exposure.

5 Q Did he also accumulate those daily doses over
6 a full year?

7 A Yes, he did. He accumulated them for a full
8 year period of time and then he added the two of them
9 together, that is the ingestion and inhalation.

10 Q As a pharmacologist do you perceive to be
11 proper and correct?

12 A No, sir, that is not correct. That is
13 incorrect. It ignores all of the basic underlying
14 principles and concepts of pharmacology and
15 toxicology.

16 Q How is that, sir?

17 A Well, it doesn't account for the metabolism
18 of carbon tetrachloride, it doesn't account for the
19 excretion of carbon tetrachloride, it doesn't account
20 for the exhalation of these two compounds or in
21 this case carbon tetrachloride in the expired air,
22 it totally eliminates the considerations for the
23 excretion of these materials from the human body,
24 which are generally pretty efficient.

25 Q These average daily doses, and I'm going to

1 refer to doses as both inhalation and ingestion,
2 for Steve Starling, I think the point -- the total
3 there is point three four?

4 A It would be point three four milligrams per
5 kilogram.

6 Q Both by inhalation and ingestion?

7 A That is correct.

8 Q In the highest year, 1977?

9 A That is correct.

10 Q Can you relate that type of dosage, daily dosage,
11 to any of your animal studies or any of the animal
12 studies with which you are familiar as they deal
13 with carbon tetrachloride?

14 A Well, that dose would never produce liver damage
15 let alone cell death in any of the animal studies that
16 I have ever conducted or in any of the literature
17 that I'm familiar with. One needs to get up to
18 60 milligrams per kilogram per day or thereabouts
19 in order to produce those kinds of liver damage,
20 either the cell damage or the production of the SGPT
21 or SGOT.

22 Q We discussed how pervasive carbon tetrachloride
23 was in our civilization. Have you seen a National
24 Institute of Health document that tells us really how
25 much the ordinary human being is exposed to carbon

1 tetrachloride and/or chloroform?

2 A Yes, I have.

3 Q What is that document called?

4 A It's called Chloroform, Carbon Tetrachloride,
5 and Other Halomethanes in Environmental Assessment,
6 and it's published by the National Academy of Sciences.

7 Q When was it published, do you know?

8 A 1978.

9 Q Does that document indicate what the National
10 Academy of Science perceives to be the exposure
11 of the ordinary human being in the United States
12 to carbon tetrachloride and chloroform?

13 A Well, it does several calculations and comes
14 up with a number of values, but I recall one being
15 around 900 milligrams per year, I believe it was,
16 for carbon tetrachloride. It will take me a minute
17 to find it if you want the exact number.

18 I'm sorry, that was for chloroform. For an
19 adult man it's 629 milligrams per year and for
20 chloroform it's 984 milligrams per year.

21 Q Tell me what type of exposure they are talking
22 about. Is that just for one year or is that for
23 more than one year? What are they saying in that
24 document?

25 A That's per year. That's the exposure to those
materials per year.

6-1

1 Q. By whom?

2 A. I am sorry. I don't understand.

3 Q. Who is being exposed to that amount?

4 MR. GILREATH: Excuse me. Could you
5 quote the page number?

6 THE WITNESS: The page number is
7 180.

8 Q. Is it a specific person, or is it a group
9 of people, or is it the whole United States?

10 A. This would be the whole United States; not
11 referring to any specific person, but it would be
12 the whole United States.

13 Q. Is that purportedly from the various compounds
14 that you described to me that are being produced
15 for the general public's use?

16 A. Yes; and also through the chlorination process
17 of water in which you create chloroform. So it would
18 be as a result of food contamination, water contamina-
19 tion and air.

20 Q. Did Dr. Rodricks make any assumptions,
21 let's say, with regard to Steve Sterling concerning
22 his total exposure of 280 milligrams per kilogram
23 for the year 1977 as shown in Exhibit 327? Do you
24 know if he made any assumptions concerning what risks
25 Mr. Sterling might have from consuming that?

1 A. Yes.

2 Q. What did he say about that?

3 A. Well, his estimation was that there was a
4 ten percent increase in risk for Mr. Sterling for that
5 particular level of exposure.

6 Q. Did he confine it to the level that was in
7 that year alone?

8 A. Yes. He confined it to the total cumulative
9 dose for that year, which was 280 milligrams per
10 kilogram.

11 MR. GENTRY: Would you mark this?

12 (The document above referred to was
13 marked Exhibit 497, for identification.)

14 Q. (By Mr. Gentry) Doctor, did you take that
15 assumption --

16 MR. GILREATH: Excuse me. Ms. Breaux,
17 what is the number?

18 THE CLERK: 497.

19 Q. (By Mr. Gentry) Did you take that assumption
20 and look at other documents and another exhibit and
21 do some calculations as it related to that assumption?

22 A. Yes, I did.

23 Q. Tell me what you did?

24 A. Okay. What I did is I took the underlying
25 assumptions for Dr. Rodricks' model, in which he

6-3

1 estimated a ten percent risk for Steve Sterling. I
2 subsequently took the doses, the cumulative doses
3 that were estimated for D. Johnson and J. Maness and
4 calculated the risk based upon a 10 percent risk
5 for Steve Sterling, which would have been 8 percent
6 and 7 percent for the latter two. Then I went to
7 the OSHA permissible exposure level for carbon
8 tetrachloride, which is 10 parts per million, and
9 using the same assumptions of the volume of air taken
10 in by Steve Sterling that Dr. Rodricks used, I calculated
11 the amounts of carbon tetrachloride that will be taken
12 in by an average worker in a one-year period of time.
13 I used that cumulative dose, that is the amount he
14 would have taken in for a period of one year, used
15 the same risk estimate, that is the same procedure,
16 and calculated the risk estimate for the average
17 worker.

18 Q. Did you also go to a document that dealt with
19 Velsicol filter operators?

20 A. Yes, I did.

21 Q. Was that Mr. Netzel's exhibit?

22 A. Yes, it was, and I used again the same assumption.

23 Q. Now, these calculations do not give validity
24 to the cumulative exposure, do they?

25 A. No, they certainly do not.

6-4

Q. And actually, as far as you are concerned -- well, withdraw that.

What result did you find using the type of extrapolation that Dr. Rodricks used?

A. Well, if we were to use the assumptions that Dr. Rodricks used and use the unusual procedure for estimating risk which he used, I have calculated using those assumptions that there should be nearly a hundred percent cancer amongst the workers who are exposed to carbon tetrachloride at the OSHA standards within two years and that they should more than all of them have cancer by the end of three years, and using the Velsicol filter operators as another example, within one year, 62 percent of them should have cancer, and within two years, a hundred and twenty-four percent.

Q. Did you hear the epidemiological study that Dr. Shindell did with reference to the heptachlor workers?

A. Yes, I did.

Q. Is there any indication that these percentages are indeed correct?

A. To the contrary, there is no indication that there is an increased incidence.

MR. GENTRY: Your Honor, we would move that this be admitted as an exhibit

6-5

1 to Dr. Harbison's testimony.

2 THE COURT: All right.

3 (Exhibit 497 received in evidence.)

4 Q. (By Mr. Gentry) Is this a proper way to do
5 a risk assessment?

6 A. No, sir, it's not.

7 Q. How do you go about doing a risk assessment
8 under these circumstances?

9 A. The way a risk assessment is conducted is to
10 use the daily exposure levels and to estimate the
11 risk for a given population of people that is based
12 upon the daily exposure level one would estimate the
13 risk of occurrence or the increased likelihood of
14 occurrence of a cancer in a thousand, a hundred thousand
15 or a million people, and expressing it as a percentage
16 is a very unusual way of estimating the risk.

17 Q. Doctor, looking at the highest daily dose
18 for Steve Sterling, Daniel Johnson and Jimmy Maness --
19 look at that if you would, please.

20 A. This is for carbon tetrachloride?

21 Q. The combination, if you will?

22 A. Of carbon tetrachloride and chloroform?

23 Q. Yes.

24 A. Okay.

25 Q. We are still referring to Exhibit 327, are we

1 not, sir?

2 A. Yes.

3 Q. Do you have an opinion as to whether any of
4 those three have an increased risk in cancer as a
5 result of the daily dose which is shown by the plaintiffs'
6 own expert?

7 A. Yes, I have an opinion.

8 Q. What is that opinion, sir?

9 A. My opinion is that there is no increased
10 risk of cancer at those doses.

11 Q. Is that an opinion based upon your expertise
12 as a pharmacologist, toxicologist, an expert in
13 cancer?

14 A. Yes, it is.

15 Q. Is that with a reasonable medical certainty?

16 A. Yes, it is with a reasonable medical
17 certainty.

18 MR. GENTRY: That's all, Your Honor.

19 THE COURT: Can we take a short recess
20 and come back at 11:30?

21 Will that be satisfactory with
22 everybody?

23 MR. GILREATH: Yes, sir.

24 (Recess.)

25 THE COURT: Go ahead, Mr. Gilreath.

5-7

1 CROSS EXAMINATION
2 BY MR. GILREATH:

3 Q. Dr. Harbison, I was looking at your CV,
4 Exhibit 352. Have you published any -- do you have
5 any publications that deal specifically with the
6 carcinogenesis of carbon tetrachloride and chloroform?

7 A. That deal specifically with the carcinogenicity
8 testing of carbon tetrachloride and chloroform?

9 Q. Yes.

10 A. No, sir, I do not.

11 Q. Do you have any publications that deal
12 specifically with the toxicology of carbon tetrachloride
13 and chloroform, specifically?

14 A. Yes, I do.

15 Q. What is that? Is that on your CV?

16 A. Yes, it is.

17 Q. What number?

18 A. I am sorry. I don't have it before me.

19 MR. GENTRY: May I hand it to him?

20 MR. GILREATH: Yes.

21 (Document handed to the witness.)

22 THE WITNESS: There is Number 81 which
23 says, "Role of biotransformation in the
24 potentiation of halocarbon hepatotoxicity
25 by 2,5-hexanedione." The two substances that

8 1 were used there were carbon tetrachloride and
2 chloroform. Those were the halocarbons.

3 Then number 84, "Potentiation of
4 chlorinated hydrocarbon toxicity by 2,5-
5 hexanediene in primary cultures of adult rat
6 hepatocytes."

7 The halocarbons are the chlorinated
8 hydrocarbons in that case where chloroform
9 and carbon tetrachloride.

10 Q. Excuse me. What is hexa --

11 A. Hexanediene?

12 Q. Yes.

13 A. Hexanediene is a ketone, which is the
14 substance that we were looking at, that class of
15 compounds, as to how they potentiate the effects of
16 carbon tetrachloride and chloroform.

17 Q. What is a ketone?

18 A. A ketone is a chemical that has a double
19 bonded "O" in it. Ketones can be used as solvents.

20 Q. Are they used in everyday things that people
21 use?

22 A. I am not aware of their contents in household
23 products. I believe they are primarily used for indus-
24 trial purposes.

25 Q. Have you done any work in the potentiation of

9 1 carbon tetrachloride and chloroform with 1,3-
2 butanedion?

3 A. Butanedion?

4 Q. Yes. B-u-t-a-n-e-d-i-o-n -- Is that the
5 way you spell it?

6 A. I don't specifically recall. We looked at
7 about ten compounds, and I am sorry, I do not recall
8 that one.

9 Q. Do you know what I am talking about --
10 B-u-t-a-n-e-d-i-o-l?

11 A. Butanediol?

12 Q. Butanediol.

13 A. Have I done any?

14 Q. Do you know what that is?

15 A. Yes, sir.

16 Q. What is it?

17 A. It is a butane that has two double bonded
18 oxygens in it. It's a diaketone.

19 Q. Diaketone. What is it used for?

20 A. I do not know.

21 Q. Is it not a fact that the FDA has approved
22 this as a flavor solvent in foods?

23 A. I am not aware of that.

24 Q. Let me show you an article that was published
25 in Toxicology and Applied Pharmacology and ask you if

C-10

1 you have ever seen that?

2 A. Yes. I am familiar with the work.

3 Q. Is that a recognized publication in the field
4 of toxicology and pharmacology?

5 A. Yes, it is.

6 Q. Have you ever seen that particular article
7 before?

8 A. I am familiar with the work of B. L. Hewitt.
9 I know him quite well, yes.

10 Q. There he did a study, did he not, of the
11 potentiation of carbon tetrachloride by the 1,3-butane-
12 diol -- how do you pronounce that, Doctor? Butadiol?

13 A. Butanediol.

14 Q. Is that what he did?

15 A. Yes, sir.

16 Q. And 1,3-butanediol is a substance that is
17 used in what, food, food emulsifiers?

18 A. It says that butanediol is used as a
19 flavor solvent and has an indirect food additive in
20 packaging films, gaskets and adhesives.

21 Q. And he found in his study, did he not, that
22 carbon tetrachloride is potentiated by 1,3-butanediol?

23 A. He says that it enhanced the hepatotoxic
24 effects, that's correct.

25 MR. GILREATH: We would like to have

-11
1 that filed as an exhibit, your Honor.

2 THE CLERK: 499.

3 THE COURT: All right, sir.

4 MR. GENTRY: Is that 498 or 499?

5 MR. GILREATH: 499.

6 (The document above-referred to was
7 marked Exhibit 499, for identification.)

8 Q. (By Mr. Gilreath) This question says, "However,
9 the most significant use of BD, as they call it, is
10 as a synthetic source of dietary calories for supplementa-
11 tion of human and animal diets."

12 Then I assume if a person is ingesting carbon
13 tetrachloride and also ingesting 1,3-butanediol,
14 that that would potentiate carbon tetrachloride
15 toxicity? Is that right, a fair statement?

16 A. Well, that paper concludes that based upon
17 the administration of some dosage of carbon tetrachloride
18 to the animals. I don't recall exactly what that was.

19 MR. GILREATH: Your Honor, I move that
20 that be received in evidence.

21 THE COURT: All right.

22 (Exhibit 499 received in evidence.)

23 Q. (By Mr. Gilreath) I believe it says in the
24 heading up there -- just read that into the record about
25 the dosage?

1 A. Okay. "Pretreatment of rats with 1,3-butanediol
2 (1.0, 5.0, or 10.0 percent in drinking water) for
3 seven days enhanced the hepatotoxic, but not the
4 nephrotoxic effects of a single dose of carbon
5 tetrachloride (0.1 milliliter per kilogram, ip) in
6 a dose-related manner."

7 Q. Enhanced the hepatotoxic, did it say?

8 A. The hepatotoxic.

9 Q. The hepatotoxic means liver?

10 A. Liver damage.

11 Q. And you say you know the author or the authors
12 of that article?

13 A. Yes, I do.

14 Q. Which one?

15 A. William Hewitt.

16 Q. Who is he?

17 A. William Hewitt was a postdoctoral student
18 with Gabriel Plaa, and I believe he is now working
19 for a drug company. However, he used to be at the
20 University of Missouri, and Gabriel Plaa was one of
21 my mentors at the University of Iowa.

22 Q. Is Dr. Plaa also one of the authors of that
23 article?

24 A. Yes, sir. Gabriel Plaa was the chairman
25 of the Department of Pharmacology at the University of

1 Montreal, and I believe he is now a Vice Dean or
2 Dean of the University.

3 Q. Is he the president of the professional
4 association that toxicologists belong to?

5 A. Yes. He is the president of the Society
6 of Toxicology, that is correct.

7 qMR. GILREATH: Would you mark this as
8 an exhibit, please?

9 (The document above referred to was
10 marked Exhibit 500, for identification.)

11 Q. (By Mr. Gilreath) Dr. Harbison, I will show
12 you what has been marked Exhibit 500, which is
13 entitled "Short Communication -- Potentiation of
14 Carbon Tetrachloride-Induced Hepatotoxicity by 1,3-
15 Butanediol," and ask you if you recognize this as
16 an authoritative work in the field?

17 A. Yes, I do.

18 Q. Does that deal with the same subject as the
19 previous exhibit?

20 A. Yes, it does.

21 MR. GILREATH: We would like to have
22 that introduced into evidence.

23 THE COURT: All right.

24 (Exhibit 500 received in evidence.)

25 Q. (By Mr. Gilreath) If 1,3-butanediol potentiates

1 carbon tetrachloride -- you were explaining earlier
2 the difference between potentiate and synergistic
3 or synergism?

4 Under potentiation your basic thesis or the
5 basic premise I believe that you gave was that a
6 substance might not have any capacity to do damage
7 unless it potentiated, is that the way you put it?

8 A. No. The substance itself, like butanediol,
9 does not have the ability or may not have the ability
10 to produce the damage itself, and that it exaggerates
11 the toxicity of the chlorinated hydrocarbon, or the
12 reverse of that. So one has an action and the other
13 one does not.

14 Q. And did I understand you to say that you have done
15 studies on the synergistic effect between carbon tetra-
16 chloride and chloroform?

17 A. Yes, sir.

18 Q. How many studies?

19 A. Let me clarify. I have done studies with
20 carbon tetrachloride and chloroform not looking at the
21 two substances together, but looking at other substances
22 which enhance the toxicity of either one of those
23 materials.

24 Q. Oh, I see. You have not done studies, putting
25 them together, just the two of them?

1 A. No, sir, I have not.

2 Q. And the substances which you have done were
3 what -- with carbon tetrachloride? Let's take carbon
4 tetrachloride.

5 A. The ketones.

6 Q. Ketones?

7 A. Yes, sir.

8 Q. Is 1,3-butanediol a ketone?

9 A. I think I have already said that yes it was,
10 but it is a diol. It is actually a two oxygen, but
11 it's an alcohol -- it's not a ketone. It has two
12 hydroxyl substitutions on it.

13 Q. Has Dr. Hewitt done any work in the potentiation
14 of chloroform or carbon tetrachloride by ketones?

15 A. I believe he has, yes.

16 (Document handed to Mr. Gentry)

17 Q. While he is looking at those, Dr. Harbison,
18 when you did your study of the effect of ketone on
19 carbon tetrachloride, did that cause any potentiation?

20 A. Yes, it did.

21 Q. How is that relevant to this case, this
22 study?

23 A. Well, I think it's relevant in that, as I said
24 before, the two classes of compounds that cause potentia-
25 tion are alcohols, like butanediol, and like hexanediol,

1 which we studied, and to the best of my knowledge,
2 those are the only two chemical classes that cause
3 potentiation of the carbon tetrachloride and
4 chloroform toxicity; not all compounds potentiate the
5 toxicity of those two compounds.

6 Q. Have you done any other studies other than
7 ketone yourself, as far as potentiation of carbon
8 tetrachloride is concerned?

9 A. Yes, sir. We have also looked at some alcohol,
10 some of the shorter chained alcohols. I don't recall
11 specifically which ones. We have looked at about,
12 I would estimate, ten different chemicals in reference
13 to that, and I can find it here.

14 This is not an up-to-date curriculum vita.

15 We presented it at the Society of Toxicology
16 meeting last year, which is essentially a study of the
17 structure activity requirements of alcohols and
18 ketones for the potentiation of chloroform and carbon
19 tetrachloride hepatotoxicity.

20 I also have a thesis -- a student has completed
21 a thesis on those studies as well, which has also
22 been published.

23 Q. Other than alcohol and ketones, have you
24 performed any other studies insofar as the synergistic
25 effects on carbon tetrachloride and chloroform or the

1 potentiation?

2 A. The only other substances which we have
3 looked at are the sedative hypnotic, and we have
4 looked at -- I believe it was phenobarbital.

5 Q. All right. Any other?

6 A. No, sir. That would be it.

7 MR. GILREATH: I will ask that this
8 be marked Exhibit 501 for identification.

9 (The document referred to above was
10 marked Exhibit 501, for identification.)

11 Q. (By Mr. Gilreath) Let me show you Exhibit
12 501, which is entitled -- it's an article from the
13 Journal of Toxicology and Applied Pharmacology, and
14 is entitled "Acute Alteration of Chloroform-Induced
15 Hepato- and Nephrotoxicity by Mirex and Kepone."

16 I will ask you if that is an authoritative
17 paper?

18 A. Yes, it is.

19 MR. GILREATH: I would offer that as
20 the next exhibit in evidence, Your Honor.

21 THE COURT: All right, sir.

22 (Exhibit 501 received in evidence.)

23 THE WITNESS: If I could make one
24 addition -- actually, we did look at Mirex
25 and Kepone as well, which are included in the

1 thesis.

2 Q. (By Mr. Gilreath) You looked at the same thing
3 that is in this article, Exhibit 501?

4 A. Yes.

5 Q. What is Mirex?

6 A. Mirex is a pesticide.

7 Q. What is its chemical content?

8 A. It's a chlorinated hydrocarbon.

9 MR. GILREATH: I will ask that this
10 be marked Exhibit 502 for identification.

11 (The document above-referred to was
12 marked Exhibit 502, for identification.)

13 Q. (by Mr. Gilreath) I will show you Exhibit 502,
14 an article from the Toxicology and Applied Pharmacology
15 Journal entitled, "Acute Alteration of Chloroform-
16 Induced Hepato-and Nephrotoxicity by n-Hexane, Methyl
17 n-Butyl Ketone, and 2,5-Hexanedione."

18 Is that an authoritative article?

19 A. Yes, it is.

20 MR. GILREATH: I will ask that Exhibit
21 502 be introduced in evidence.

22 THE COURT: All right, sir.

23 (Exhibit 502 received in evidence.)

24 MR. GILREATH: I will ask that this
25 be marked Exhibit 503 for identification.

1 (The document above referred to was
2 marked Exhibit 503, for identification.)

3 Q. (By Mr. Gilreath) I will show you exhibit 503,
4 an article from Toxicology and Applied Pharmacology,
5 entitled Role of Biotransformation in the Alterations
6 of Chloroform Hepatotoxicity Produced by Kepone and
7 Mirex."

8 I will ask you if that is an authoritative
9 article?

10 A. Yes, it is.

11 MR. GILREATH: I will ask that that
12 be introduced in evidence, Your Honor.

13 THE COURT: All right, sir.

14 (Exhibit 503 received in evidence.)

15 MR. GENTRY: Your Honor, I am not
16 making any objection to these studies. I
17 am just curious, in light of the fact
18 that there is really no cross examination
19 on any of these studies, as to the status
20 of those studies in the record. Are they
21 for the truth of the matter spoken therein?
22 Are they for identification as authoritative
23 articles? We would just like a clarification
24 from the plaintiff, if the Court please.

25 THE COURT: All right, sir.

1 MR. GILREATH: Well, Your Honor, the
2 purpose of the article is Dr. Harbison
3 has indicated he has done his own studies
4 in potentiation of carbon tetrachloride
5 by certain compounds, and it looks like that
6 he has done the same studies that these people
7 have, and we are introducing these to show --
8 and I think he has already testified -- that
9 carbon tetrachloride is potentiated by certain
10 other chemical compounds, which include kepone
11 and mirex and butanediol, which is a food
12 additive. That's the purpose of these articles.

13. end
14
15
16
17
18
19
20
21
22
23
24
25

1 MR. GENTRY: Your Honor, that's fine,
2 with the exception that the butanediol I don't
3 believe is a food additive. It is an indirect
4 food additive, which is substantially different
5 from an active food additive. That's what
6 I thought they were saying and I just wanted
7 to clarify that.

8 THE COURT: All right, sir.

9 BY MR. GILBREATH:

10 Q Now, did I understand you to say on direct
11 examination, Dr. Harbison, that carbon tetrachloride
12 and chloroform were not potentiated by chlorinated
13 hydrocarbon?

14 A By those chlorinated hydrocarbons which are
15 ketones they are. The chemical classes that
16 potentiate the toxicity of chloroform and carbon
17 tetrachloride are ketones and alcohols.

18 Q All right. Is butanediol an alcohol?

19 A Yes, sir, it is.

20 Q According to this article, Exhibit 499, it's
21 used as a flavor solvent in food, as an indirect food
22 additive in packaging films, it's used as a food
23 preservative, and it's used as a food emulsifier.
24 What do you mean by food emulsifier?

25 A I'm not sure what that means. I think alcohols

1 in general are used to create stable emulsions and by
2 adding small amounts of alcohols you can change the
3 emulsion qualities of various materials.

4 Q All right. In this article it says that
5 "the in vitro binding" -- what does in vitro mean?

6 A It means outside of the organism.

7 Q -- "in vitro binding of carbon tetrachloride-
8 derived radioactivity to microsomal protein was
9 increased both aero"-- I can't --

10 A It's aerobically and anaerobically, I believe.

11 Q Right. --"but was greater under aerobic
12 conditions. BD appeared to potentiate carbon
13 tetrachloride liver injury, at least in part by producing
14 an increase and/or alteration in mixed function
15 activation of carbon tetrachloride to toxic metabolites."

16 Did you find that true in your studies?

17 A Yes, sir, we did. We found that it was
18 necessary to have a change in the metabolic activity
19 to have the potentiation occur for the carbon
20 tetrachloride and chloroform.

21 Q "Thus, BD potentiation may arise through
22 several interrelated pathways."

23 Is that true?

24 A Yes, I would agree with that.

25 Q You did not do any tests to determine the

6-3

1 synergistic effect between carbon tetrachloride --
2 you already said in chloroform -- nor did you do
3 any between, say, toluene and carbon tetrachloride
4 or benzene?

5 A No, sir, I did not, because there would be
6 no reason to suspect that occurred.

7 Q Now, you were a part -- when did you do your
8 tests that you were talking about?

9 A The general ones of the chloroform and carbon
10 tetrachloride?

11 Q Yes.

12 A Those studies began when I was at Vanderbilt.
13 The student thesis probably developed over probably
14 the past five years, so I would estimate somewhere
15 around 1977, '78.

16 Q That was about the time or it was about that
17 same time that you were a part of the task force in
18 this case, is that right?

19 A That is correct.

20 Q And you were -- that task force had meetings
21 with AWARE, I believe? Were you working for AWARE
22 then or were you working for Velsicol?

23 A No, sir, I was a consultant to AWARE.

24 Q And at that time was it Velsicol's intention --
25 did you talk to them about them doing a health study?

1 A Did I talk to them personally?

2 Q Or did they talk to you or was it --

3 A No, sir, to the best of my recollection there
4 was no such discussion.

5 Q There was never any discussion that you know
6 about about Velsicol going to do a health study on
7 the people at Hardeman -- at Toone?

8 A No, that discussion did occur, but it did not
9 occur with me specifically.

10 Q All right. Who did it occur with?

11 A Well, it was discussed amongst the task force
12 on several occasions and that's about all the
13 recollection that I have of that particular matter.

14 Q Now, you have been speaking this morning about
15 carbon tetrachloride and chloroform or at least Mr.
16 Gentry has been talking in terms of most questions
17 would be carbon tetrachloride and chloroform used
18 interchangeably. Insofar as toxicity, are they in
19 the same ball park or in the same --

20 A They are similar, yes, sir.

21 Q So insofar as harmful effects are concerned,
22 they are similar insofar as toxicity?

23 A Yes, sir, they would be similar.

24 Q He also -- or you went through certain principles
25 of the toxicology in your direct, and I'd like to go

1 over some of those principles of toxicology with you
2 that I've kind of gone into. I'd like to show you
3 what's been marked as Exhibit Number 498, entitled
4 Principles of Toxicology. That is my own term --
5 my own terminology for this. Looking at Page 1,
6 the first one is "Chlorinated hydrocarbons are
7 manmade, and occur rarely, if ever, in nature."
8 Is that true?

9 A That's probably not totally true. There is
10 some evidence now that those compounds in fact
11 probably do occur naturally and probably are created
12 in the troposphere as the result of irradiation.

13 Q So you would disagree at least to that extent
14 with that statement?

15 A Yes, sir.

16 Q "Extensive experience and research with these
17 chemicals has led to an awareness that adverse health
18 effects can result from exposure to low concentrations
19 of these chemicals."

20 A Yes, sir.

21 Q That's true?

22 A Yes, it is.

23 Q "We have also discovered that some of these
24 compounds also can cause cancer, birth defects and
25 possibly mutations after exposure to low

1 concentrations."

2 A I would agree with that.

3 Q "In addition, these compounds are hepatotoxic
4 (toxic to the liver) nephrotoxic (toxic to the kidneys)
5 and neurotoxic (toxic to the central and peripheral
6 nervous system)."

7 A I would agree with that.

8 Q On Page 2: "Cells that have been damaged in a
9 nonspecific way invariably perform less well than
10 normal cells, whereas cancer cells not only survive
11 in competition with normal cells, but have a selective
12 advantage over them."

13 Is that generally true?

14 A Yes, sir.

15 Q Number 3: "First, epidemiological methods
16 are insensitive and may only detect extremely large
17 increases in cancer risk. The lower limit of
18 detection by these methods has been approximately a
19 30 percent increase in cancer."

20 Does that sound okay so far?

21 A Yes, sir.

22 Q "Even a 10 percent increase in cancer would
23 be unacceptable, although it would be undetectable in a
24 study of human populations."

25 Is that --

1 A I would agree with that.

2 Q "Second, clinical cancers only appear in humans
3 exposed to carcinogens after substantial lag periods;
4 typically on the order of 15 to 30 years."

5 A I would agree with that.

6 Q Number 4: "For the reasons stated, animal tests
7 have become our principal source of information about
8 which chemicals pose a cancer risk in humans. The
9 animals most often used as models are rodents, usually
10 rats and mice. These animals are good predictors of
11 human cancer risk, although arguments can be made
12 that they are in fact not as sensitive to carcinogens
13 as humans."

14 A I would agree with that.

15 Q We do know that these rodents, then, are not
16 as sensitive to carcinogens as humans?

17 A No. I think it says that an argument can be
18 made. I don't think we can make general statements.
19 We have to refer to specific compounds.

20 Q Okay. Number 5: "Animal test models are
21 used for two purposes. The first is to identify
22 chemicals which are capable of causing cancer,
23 regardless of the dose. Properly designed animal
24 studies use as their highest dose the maximally
25 tolerated dose, defined as a dose which causes no

1 observable lethal or sublethal tissue damage and
2 results in no more than 10 percent weight loss in the
3 exposed versus unexposed groups. High doses are
4 used in order to produce cancers at a rate high
5 enough to be detected with animal populations of
6 practicable size. If the substance is not a
7 carcinogen, and most are not, it will not increase tumor
8 risk at any dose. The only serious question presented
9 in such modeling is whether a chemical can be a
10 carcinogen at a high dose but not at a low dose,
11 i.e., whether a 'safe' threshold exists. A great deal
12 of independent biologic evidence suggests that there
13 is no such safe threshold. The presumed mechanism
14 of cellular transformation discussed above supports
15 the same view and measurement of tumor risk
16 at low dose levels is statistically inaccessible to
17 practical determination. Second, these tests aid in
18 estimating the extent of the increased risk of cancer
19 at low doses, given high dose data. These estimates
20 are made on the basis of mathematical extrapolations
21 of the high doses which have been shown to cause cancer.
22 None of the several competing models of low dose
23 extrapolation in use assume a 'safe' threshold.
24 Disagreements on the proper model to use do not
25 involve whether the chemical can cause cancer at

1 low doses; such disagreements rather pertain to
2 how much cancer it can cause."

3 Do you agree with that?

4 A Yes, sir, I do.

5 Q Number 7: "Animal tests are used to identify
6 chemicals which are capable of causing birth defects.
7 The animal tests are used in estimating the extent
8 of the increased risk of birth defects. There is a
9 better than 90 percent correlation between
10 substances which give positive and negative responses in
11 these animal tests. Evidence based upon the
12 techniques described above has shown that the inorganic
13 compounds, and the organic compounds including
14 chlorinated hydrocarbons . . . are toxic and in many
15 cases are carcinogens, teratogens and mutagens."

16 Do you agree with that?

17 A Yes, sir, I would.

18 Q Number 8: "Chloroform is an established animal
19 carcinogen causing cancers in several strains of mice,
20 in rats, and probably in dogs. These animal models
21 have shown that the affected organs include the
22 liver, kidney and thyroid. Several epidemiological
23 studies on human populations exposed to chloroform in
24 public drinking water have shown correlations between
25 chloroform and population cancer rates. On the basis

1 of available animal and human data, exposure to
2 chloroform in drinking water increases the risk
3 of cancer, birth defects and abortions."

4 Do you agree with that?

5 A No, sir, I do not.

6 Q You do not?

7 Number 9: "Chlorinated hydrocarbons are
8 known to cause -- are known to damage the liver, kidney,
9 heart and nervous systems. Chlorinated hydrocarbons
10 are suspected of causing cancer and birth defects. On
11 the basis of animal -- of available animal and human
12 data, exposure of chlorinated hydrocarbons in
13 drinking water increases the risk of cancer,
14 birth defects and organ toxicities."

15 Do you agree with that?

16 A I don't agree with it in terms of its generality.
17 It would have to depend on which compounds we are
18 talking about.

19 Q It would have to depend on what?

20 A It would be compounds specific, that is which
21 ones we were referring to that might produce those
22 changes.

23 Q Say chloroform?

24 A It would depend on the level to which the
25 individual was exposed or the level of the water

1 contamination.

2 Q And you disagree with that as a general statement
3 about chloroform?

4 A Well, I disagree with it in the sense that
5 it does not relate to the level of exposure, and
6 unless I know what the level of exposure is I can't
7 agree with the statement.

8 Q Well, let's take the level of exposure on
9 Exhibit Number 375, which is the average concentrations --
10 average annual concentrations in ppb on the Sterling
11 and Johnson wells and the Mosier well. Assuming
12 those levels of exposure, would you agree with that
13 statement?

14 A No, sir, I would not.

15 Q We are talking about chloroform levels in the
16 drinking water in 1978 of 950 and 970 ppb?

17 A That is correct.

18 Q Now, going back to number 8, let's take
19 number 8 first. What is there about number 8 that
20 you disagree with?

21 A Well, I think that there has been a change
22 conceptually regarding the toxicity produced by
23 chloroform and I would not agree, but again it's
24 going to depend on the level at which the chloroform
25 is in the water as to whether or not there might be

1 some possibility of producing any of those effects.

2 Q Haven't you in the past testified to that
3 statement on Page 8?

4 A Yes, sir, I have.

5 Q And where was that?

6 A I believe that testimony was in New Jersey.
7 I can't remember exactly. I believe it was Atlantic
8 City, New Jersey.

9 Q And in making that statement have you changed
10 your mind since then?

11 A Well, I agree that chloroform is an established
12 animal carcinogen. I agree with the statement that
13 it causes changes in mice and rats.

14 Q It causes cancer to several strains of mice
15 and rats, is that right?

16 A That's correct. I do not agree with the
17 statement about chloroform and its correlation with
18 cancer rates in humans.

19
20
21
22
23
24
25

7-1 1 Q. When you made this statement in New Jersey,
2 what was the level of chloroform in the drinking
3 water that you were looking at there?

4 A. I can't recall.

5 Q. Do you recall whether it was lower or higher
6 than the concentrations in the exhibit there on the
7 board?

8 A. I am sorry. I can't recall.

9 MR. GILREATH: Would you mark this
10 as an exhibit for identification?

11 (The document above referred to was
12 marked Exhibit 504 for identification.)

13 MR. GENTRY: May I see it?

14 (Document handed to Mr. Gentry.)

15 Q. (By Mr. Gilreath) Do you recognize that
16 exhibit?

17 A. Yes, I do.

18 Q. That is an affidavit which you filed in the
19 case in New Jersey, is that correct?

20 A. That is correct.

21 Q. And on page 11 under "Chloroform --

22 A. Yes, sir.

23 Q. Starting down about the third of the way
24 down on the righthand side of the page where it says,
25 "Chloroform is an established animal carcinogen."

1 A. Yes, sir. I see that.

2 Q. Would you read that to the end of the
3 paragraph for me?

4 A. Okay.

5 (Reading) "Chloroform is an established
6 animal carcinogen causing cancers in several strains
7 of mice, in rats, and probably in dogs. These
8 animal models have shown that the affected organs
9 include the liver, kidney and thyroid. Several
10 epidemiological studies on human populations exposed
11 to chloroform in public drinking water have shown
12 correlations between chloroform and population cancer
13 rates. On the basis of animal and human data, exposure
14 to chloroform in drinking water increases the risk
15 of cancer, birthdefects and abortions."

16 Q. Now, that's the same statement that is on
17 page 8 of the previous exhibit, is that correct?

18 A. That's right.

19 Q. Now, you were looking at chloroform -- in this
20 case you were testifying for the EPA, is that right?

21 A. For the United States Department of Justice.

22 Q. And in this case it involved a landfill in
23 New Jersey?

24 A. That is correct.

25 Q. And in that landfill they had polluted the

7-3 1 drinking water of some of the residents?

2 A. Well, actually it was polluting the drinking
3 water of Atlantic City, New Jersey.

4 Q. And in this case you were using, you and the
5 government, you as the witness, were using the water
6 quality criteria by the EPA as your standard?

7 A. That is correct.

8 Q. And by the water quality criteria we mean
9 what?

10 A. The water quality criteria are levels which
11 the U. S. EPA has generated which identify health
12 risks that might be associated with exposure to
13 those for some period of time.

14 Q. All right. Now, over on page 14 of your
15 affidavit is shown "EPA Well No. 1A." Do you see
16 that?

17 A. Yes, sir.

18 Q. And in that well is shown under "Chloroform"
19 68 ppb?

20 A. That is correct.

21 Q. And your statement was, "This level is
22 approximately the 350 times greater than Water
23 Quality Control standards." Is that true?

24 A. That is correct.

25 Q. And how many times greater would the 960--

1 950 -- 950, rather, 1973 in the Johnson and Starling
2 well be -- how many times greater than the Water
3 Quality Control Standard would that be?

4 A. The Water Quality criteria -- it would probably
5 be several hundred.

6 Q. Well, 68 is 350 times?

7 A. Yes, sir.

8 Q. ppb?

9 A. Yes, sir.

10 Q. And that's several times that, even, isn't
11 it?

12 A. Well, that's 970 parts per billion; so it's
13 a larger concentration.

14 Q. Well, the concentration in your well number 1A
15 on your affidavit was 68 parts per billion.

16 A. That's right.

17 Q. And you testified in this case that that was
18 unsafe?

19 A. Well, I testified that the general composition
20 of the water for regulatory purposes was not safe
21 for continued consumption by the population of people
22 who would have been exposed, which is not only these
23 people, but the Atlantic City waterintake, and it
24 includes a variety of other materials.

25 Q. And on page 9 -- what is the exhibit number,

1 the Principles of Toxicology -- what is your Exhibit
2 number on that?

3 A. That's Exhibit 498.

4 Q. 498?

5 A. Yes.

6 Q. On page 9 of Exhibit 498 is the statement
7 that comes from page 12 of your affidavit, does it
8 not?

9 A. Yes, sir.

10 Q. Now, on page 14 of your affidavit you show
11 tetrachloroethylene at 9 ppb.

12 A. Yes, sir.

13 Q. In Well No. 1, which exceeds the Water Quality
14 Control -- water quality criteria?

15 A. That's correct.

16 Q. And then on page 15 you show in Well No. 2
17 chloroform at 123 ppb -- that this level exceeds the
18 water quality criteria by 647 times.

19 A. That's correct.

20 Q. What is the number of the exhibit for the
21 affidavit?

22 A. That's 504.

23 MR. GILREATH: Your Honor, we would
24 like to have Exhibit 504 introduced in
25 evidence.

1 THE COURT: All right, sir.

2 (Exhibit 504 received in evidence.)

3 Q. (By Mr. Gilreath) Would you read into the
4 record from page 11 under "Chloroform" down to where
5 it ends with the word "System."

6 A. I am sorry. I don't find "System," here.

7 Q. Okay. We read the other. Let me show you.

8 A. I see. Do you want me to read the rest of the
9 paragraph?

10 Q. Yes.

11 A. "Trichloromethane or chloroform is an industrial
12 solvent and chemical intermediate used in the production
13 of other chemicals. Chloroform is completely absorbed
14 when ingested in drinking water and is then distributed
15 throughout the body. The highest concentrations are
16 found in the peripheral nerves. Rats exposed to
17 chloroform have shown retarded development and
18 reduced birth weights and in one study, an increased
19 rate of malformation was found. Chloroform sensitizes
20 the heart, increasing the possibility of fatal cardiac
21 arrhythmia (sudden death.) The lowest doses at which
22 this condition might occur are not known. At high
23 doses it is toxic to the liver, kidney and central
24 nervous system."

25 Is that where you want me to stop?

1 A. Yes. We already read the rest of that in,
2 I believe, did we not?

3 A. I think that's correct.

4 Q. So chloroform does attack the central nervous
5 system?

6 A. Chloroform has the pharmacological properties
7 of being able to alter the function of the nervous
8 system. However, it does that only at high
9 concentrations.

10 Q. Well, you just stated here that the lowest
11 dosage at which this condition might occur are not
12 known. Is that true?

13 A. I believe that I was referring there to the
14 heart in the sensitization of the heart tissue and
15 the production of cardiac arrhythmias.

16 Q. Well, you didn't say anywhere in this statement
17 that this only occurs in high dosage, did you?

18 A. No, sir, I did not.

19 Q. Would you read into the record Paragraph No.
20 38, on page 19.

21 A. Part of it is blurred out. Number 38?

22 Q. Yes.

23 A. (Reading) "I am concerned as a scientist
24 about the many contaminants and their quantity
25 which have been identified in the water surrounding

1 -- and then it is blanked out -- in my judgment
2 as a toxicologist, individuals using private wells
3 in the area of the landfill sites should not be exposed
4 to these chemical contaminants in water used for
5 drinking or other purposes, such as bathing. As is
6 evident from my previous observations, the presence of
7 most of these contaminants in public drinking water
8 supplies in any significant quantities would present
9 an extremely serious public health problem."

10 Q. Now, the short term effects of the chlorinated
11 hydrocarbons are irritation of the eyes, irritation
12 of the throat, skin eruptions, central nervous
13 system effects, depression -- is that true?

14 A. Well, at certain levels of exposure to
15 chlorinated hydrocarbon those things can occur, that
16 is correct.

17 Q. Well, if those things occur in the presence
18 of chlorinated hydrocarbons, then it would be
19 natural to assume that the levels of exposure were --
20 that the levels were enough to cause it, would it not,
21 assuming you had those conditions?

22 A. No, sir. Those conditions can be caused by
23 other things as well.

24 Q. What are the long term effects of chlorinated
25 hydrocarbons?

1 A. Well, the long term effects, again, depending
2 on the dose, might be organ injury, damage to the
3 liver.

4 Q. Injury to the respiratory system?

5 A. That is a possibility.

6 Q. Injury to the blood forming system?

7 A. Yes, sir.

8 Q. Injury to the nervous system?

9 A. Yes, sir.

10 Q. Now, that can occur as a result of low level
11 exposure, can't it?

12 A. In general, those effects will be seen only
13 with high exposure, and generally with chlorinated
14 hydrocarbons that are much larger in molecular weight
15 than chloroform and carbon tetrachloride.

16 Those things generally occur with the higher
17 chain chlorinated hydrocarbons.

18 Q. Didn't you testify in the Price Pit case
19 that these conditions can occur as a result of long
20 term low level exposure?

21 A. I don't recall that testimony. I may have.

22 MR. GILREATH: I will ask that this
23 be marked for identification.

24 (The document above-referred to was
25 marked Exhibit 505, for identification.)

1 Q. (By Mr. Gilreath) Is that a copy of your
2 testimony in that case, Exhibit 505?

3 A. Yes, it is.

4 Q. Would you look at page 23?

5 A. Yes.

6 Q. Look at line 13 --

7 "Q. Could you advise the court what such
8 short term effects generally are in terms of these
9 toxic chemicals?"

10 And then read your answer.

11 A. (Reading) "A. The short term effects would
12 be various irritations such as irritation of the eyes,
13 the throat, causing coughing, perhaps skin eruptions,
14 things like chloracne or pimples as a result of exposure
15 to various chlorinated hydrocarbons. General nuisance
16 irritation problems as a result of exposure which
17 lasts for a short term occur very soon after exposure."

18 Q. And the next question --

19 "Q. Are central nervous system effects
20 also short term or acute effects?"

21 And then your answer.

22 A. (Reading) "A. Central nervous system effects
23 such as depression, unconsciousness or affecting
24 the central nervous system in one way or another to
25 impair motor activity would be a short term effect."

1 Q. And the next question --

2 "Q. Now, in addition to the short term effects,
3 Dr. Harbison, can you advise us what long term effects
4 or chronic effects may occur?"

5 Would you read your answer?

6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
end

1 A "The long term effects or chronic effects
2 are generally thought of as being either specific
3 organ injuries, such as injury to the respiratory
4 system or injury to the blood forming system
5 or injury to the nervous system which occurs as a
6 result of long term, low level exposure to various
7 substances. Examples of that might be lead
8 encephalopathy, an alteration of nervous system
9 function as a result of long term, low level
10 exposure to lead. The other chronic effects that are
11 of concern and that are generally thought of are birth
12 defects or the production of birth defects, which is
13 known as a teratogen or teratogenicity. The
14 production of mutations in genetic material of
15 germinal cells which will affect future generations
16 and the production of cancer which would be an effect
17 on genetic material of somatic cells or all other,
18 the egg or the spermatozoa."

19 MR. GILREATH: Your Honor, we'd like
20 to move that Exhibit 502 --

21 THE CLERK: 505.

22 MR. GILREATH: -- 505 be admitted.

23 THE COURT: All right. This is the last
24 document you had reference to?

25 MR. GILREATH: Yes.

1 THE COURT: All right, sir.

2 MR. GILREATH: Exhibit 505 is testimony
3 in the United States District Court for the
4 District of New Jersey.

5 (Whereupon, the above-mentioned
6 document was marked Exhibit Number 505
7 to the testimony of the witness and same
8 will be found among the exhibits hereto.)

9 BY MR. GILREATH:

10 Q Now, insofar as the water quality guide of the
11 EPA is concerned for suspected carcinogens, which is --
12 chloroform is one and carbon tetrachloride under
13 their criteria, is that right?

14 A That is correct.

15 Q Insofar as risk evaluation or risk determination
16 is concerned, no level is safe, that's what they say,
17 isn't that right?

18 A Well, the EPA says that there is no scientific
19 basis for any model for making judgments about
20 safety and, therefore, since there is no scientific
21 basis for that as an interim action they will assume
22 that there is no safe level.

23 Q And that's what you so testified in this
24 Price's pit case, that was your testimony?

25 A You mean did I testify that the water quality

1 criteria were -- I'm not sure I understand your
2 question.

3 Q Did you not testify that methods do not now
4 exist to establish a threshold for a carcinogen
5 and that there is no scientific basis for estimating
6 the safe level, therefore there is no safe level
7 for a carcinogen in drinking water?

8 A Well, sir, I only testified in reference to the
9 compounds that were found in those wells, which
10 include the longer chain chlorinated hydrocarbons
11 like vinylchloride, which included the chlorinated
12 benzenes, the naphthalenes. For those substances
13 that is a different consideration. For carbon
14 tetrachloride and chloroform that is not a consideration.

15 Q Is not chloroform and carbon tetrachloride
16 a suspected carcinogen?

17 A Yes, sir, it is.

18 Q Then doesn't that quality control guide apply
19 to those suspected carcinogens? Isn't that what it
20 says?

21 A The water quality criteria, yes, sir, it does.

22 Q So if you applied that rule, then, then there
23 would be no safe levels for carbon tetrachloride
24 and chloroform under that rule?

25 A Under the rule of the water quality criteria,

1 that's correct.

2 Q And that's the rule that you were advocating
3 when you were testifying for EPA in that case?

4 A Well, I was advocating that rule based upon
5 a regulatory process to prevent the utilization of
6 water by the city of Atlantic City that contained
7 these materials.

8 Q Well, you wouldn't apply a different rule to
9 this Hardeman County situation, would you?

10 A Yes, sir. I think there's a very different
11 rule. What we are talking about is causation and
12 that differs significantly from regulatory standards.

13 MR. GILREATH: I think I'm about through,
14 Your Honor.

15 BY MR. GILREATH:

16 Q Dr. Harbison, are you familiar with a study
17 involving a human being who was cleaning his gun with
18 carbon tetrachloride, he had a couple of drinks and
19 caused a peripheral neuritis and there was a study done
20 on this person? Do you recall that study?

21 A No, sir, I do not.

22 MR. GILREATH: That's all we have.

23 THE COURT: All right, sir.

24 MR. GENTRY: Your Honor, I will be about
25 fifteen or twenty minutes on redirect.

1 THE COURT: All right. Do you want to
2 come back at 1:45? Will that be all right?

3 MR. GILREATH: Can we finish that now?
4 We have got a witness that needs to get
5 on after lunch.

6 MR. GENTRY: I don't see how that is going
7 to make a lot of difference if we are going
8 to break for lunch immediately afterwards.

9 MR. GILREATH: All right.

10 THE COURT: All right.

11 (Recess.)

12 THE COURT: All right, Mr. Gentry.

13 MR. GENTRY: I'm waiting for Mr. Gilreath.

14 THE COURT: Oh, okay.

15 MR. GENTRY: May we proceed, Your Honor?

16 THE COURT: Yes, sir.

17 REDIRECT EXAMINATION

18 BY MR. GENTRY:

19 Q Dr. Harbison, I'd like to take Exhibit 498,
20 which is entitled Principles of Toxicology written
21 on top of the exhibit, and paraphrase the first one
22 a little bit, if I may.

23 Carbon tetrachloride and chloroform are manmade
24 and occur rarely, if ever, in nature.

25 Is that true or false?

1 A Well, it's partially true and partially not
2 true.

3 Q Still talking in terms of carbon tetrachloride
4 and chloroform as opposed to chlorinated hydrocarbons:

5 Extensive experience and research with these
6 chemicals has led to an awareness that adverse health
7 effects can result from exposures -- exposure to
8 low concentrations of these chemicals, carbon
9 tetrachloride and chloroform.

10 What would you say to that?

11 A I would say that's not true.

12 Q "We have also discovered that some of these
13 compounds" -- and let's just say that we have also
14 discovered that carbon tetrachloride and chloroform
15 also can cause cancer, birth defects and possibly
16 mutations after exposure to low concentrations.

17 A That is not true.

18 Q In addition, carbon tetrachloride and chloroform
19 are hepatotoxic, nephrotoxic, and neurotoxic.

20 A That is partially true.

21 Q How many chlorinated hydrocarbons are there,
22 sir?

23 A There are hundreds, thousands.

24 Q What's the difference between carbon tetrachloride
25 and chloroform and chlordanes?

1 A The number of carbons in the molecule, the
2 amount of chlorine on the molecule, the basic structure
3 of the molecule, its physical properties, both its
4 physical and chemical properties.

5 Q The molecular weight?

6 A Molecular weight is considerably different.

7 Q Is the difference in molecular weight a
8 critical difference?

9 A Yes.

10 Q Carbon tetrachloride and chloroform, are they
11 high molecular weight or low molecular weight
12 chlorinated hydrocarbons?

13 A They are low molecular weight.

14 Q Dr. Harbison, tell me about this United
15 States versus Charles Price, et al. When did this
16 occur?

17 A Well, I believe it was late 1979 or sometime
18 in 1980. I can't recall the exact date.

19 Q And you were a witness for whom?

20 A I was a witness for the United States Department
21 of Justice.

22 Q They were bringing an action under what?

23 A Under the Clean Water Act.

24 Q And they were basing their action against these
25 people on what?

1 A Well, on the changing of the quality of the
2 water that had been there and based upon the use of
3 that water for public drinking.

4 Q Were they relying upon the water quality criteria
5 as set up by the EPA?

6 A Yes, they were.

7 Q Do you discuss in your affidavit what the water
8 quality criteria means?

9 A Yes, I do.

10 Q Where do you do that, sir?

11 35?

12 A I haven't found it yet.

13 Q On Page 12.

14 A Right, it's 35.

15 Q Read that to the Court, please.

16 A "Following the passage of legislation in the
17 Congress, the United States Environmental Protection
18 Agency promulgated standards designed to ensure that
19 the American public is not exposed to dangerous levels
20 of toxicant drinking water. These standards are
21 expressed in terms of risk analysis. While U.S. EPA
22 suggests that no exposure to carcinogens occur in
23 drinking water, it has expressed its standards in terms
24 of estimated risks from these contaminants. These
25 estimates are based upon the scientific information to

1 which I have previously referred. The Water Quality
2 Criteria are expressed in terms of one additional cancer
3 per one million population as a function of a
4 lifetime exposure to the particular carcinogen. The
5 most recent publication of the standards appear in
6 the Federal Register on November 28, 1980 and is
7 attached as Exhibit B to this affidavit. The
8 Water Quality Criteria are a useful guide to risk
9 assessment from chemical exposure and will be referred
10 to by me in my analysis of data in this case."

11 Q Now, there is an exhibit that is the Water
12 Quality Criteria, is there not?

13 A That's correct.

14 Q Can you turn to Page 79323 of the Water Quality
15 Criteria and read the first paragraph or the first
16 couple of sentences designated "Risk Extrapolation".

17 A Okay, it's entitled "Risk Extrapolation."

18 "Because methods do not now exist to establish
19 the presence of a threshold for carcinogenic effects,
20 EPA's policy is that there is no scientific basis
21 for estimating 'safe' levels for carcinogens."

22 Do you want me to proceed?

23 Q Yes, please.

24 A "The criteria for carcinogens, therefore,
25 state that the recommended concentration for maximum

1 protection of human health is zero."

2 Q All right. Now, drop down to Health Guidelines
3 in the next paragraph, and there's a phrase which
4 commences "The estimation of health". Do you see
5 that?

6 A Yes, I do.

7 Q Read that.

8 A "The estimation of health risks associated with
9 human exposure to environmental pollutants requires
10 predicting the effect of low doses for up to
11 a lifetime in duration."

12 Q Are those scientific statements or policy
13 statements?

14 A Those are policy statements.

15 Q Are those statements directed to genotoxic
16 carcinogens?

17 A Yes, sir, they are.

18 Q And what did you tell me a genotoxic carcinogen
19 was?

20 A A genotoxic carcinogen is one that is able to
21 interact with the genetic material of the cell and
22 cause a change in that cell to initiate cancer.

23 Q Would that be -- withdraw that question.

24 Do you have the transcript of the hearing in
25 front of you, sir?

1 A Yes, I do.

2 Q Can you turn to Page 28 for me, please?

3 A Yes.

4 Q Do you see line 8 there? And I'll start with
5 the question, if I may, and I will let you answer
6 the questions. Will you do that with me?

7 A Yes.

8 Q "Now, we've described the tools which
9 toxicologists use in identifying problems caused by
10 chemicals. We've also talked about the results
11 from a toxicological standpoint in terms of their.
12 short term and long term effects. By the way, in
13 terms of long term effects, Dr. Harbison, can you give
14 us a time frame? We talked about chronic or long
15 term, but what is generally meant from a toxicological
16 standpoint in terms of years?"

17 What's your response?

18 A I'm sorry, give me the page again.

19 Q Do you have the transcript? Not your
20 affidavit, the transcript.

21 A Yes, I have the transcript.

22 Q It would be 26, as near as I can see.

23 A I'm sorry, I thought you said 28.

24 Q It looks like 28 and I believe it's 26.

25 A Okay. Line 187

1 Q Yes.

2 A Okay. "For carcinogenicity or the production
3 of cancer, it is generally thought of to be fifteen
4 to thirty years. That is the time from exposure
5 until the disease actually occurs. For mutagenicity
6 it's thought to be at least one generation, which
7 would be approximately twenty-two years. And for
8 teratogenicity it could be anywhere from a few weeks
9 to probably more like eight to nine months."

10 Q Now, before I read the next question, I'd like
11 to ask you, are we referring to genotoxics there?

12 A Yes.

13 Q The next question is:

14 "In any event, Doctor, we have discussed the
15 tools that toxicologists use, the effects that are
16 generally observed through the use of those tools.
17 I wonder if you could advise the Court when one is
18 dealing with the human being or the human system
19 what the entry points are that these chemicals may
20 attack or actually get into the body to cause the
21 type of effects which we have just described?"

22 A "Chemicals can get into the human system by
23 one of three ways. They can be"-- It says observed,
24 but I'm sure that should be absorbed -- "across the
25 surface of the skin, which is known as percutaneous

1 absorption. They can be" -- again it says observed,
2 but I think it should be absorbed -- "from the
3 gastrointestinal tract view contaminants in food or
4 drink, and they can also be absorbed through the
5 respiratory tract if they are airborne either as
6 a mist or vapor or somehow suspended in the air."

7 Q Now if you would turn over to Page 28, we
8 are talking about mechanisms for the production of
9 cancer and the attorney questions you:

10 "I wonder if you could advise the Court what
11 those mechanisms are?"

12 A "Well, there are at least two. And one is a
13 genetic mechanism, the genetic mechanism being the
14 direct interaction of the chemical with DNA of various
15 cells of the body. The other mechanism is an
16 epigenetic mechanism and tumors or transformation
17 of cells into cancerous cells occurs as a result of
18 toxic recurrent tissue injury from exposure to an
19 irritant or some chemical to produce various tissue
20 damage."

21 Q The chemical that produces the genetic
22 mechanism, is that a genotoxic chemical?

23 A Yes, it is.

24 Q And what kind of chemical would produce the
25 epigenetic mechanism?

1 A That would be substances like carbon tetrachloride
2 and chloroform.

3 Q Is that testimony consistent or inconsistent
4 with the testimony you have given here today?

5 A That testimony is consistent.

6 Q Would you turn to Page 31, please, sir.

7 A Yes.

8 Q At the top of the page, I believe it's Mr.
9 Walsh says:

10 "Dr. Harbison, you were talking about the
11 routes in which chemicals can cause cancer in human
12 beings. I wonder if with reference to 408 you
13 could describe those various pathways?"

14 I'm assuming 408 was an exhibit.

15 A Yes, sir.

16 Q What is your answer there?

17 A "What we are talking about, two specific
18 mechanisms whereby chemicals can introduce cancer
19 as a result of interaction with the cells. The two
20 pathways are one, a genotoxic pathway or genetic
21 time mechanism whereby the chemical interacts with --
22 directly with DNA. There is an interaction which --
23 which occurs with DNA to alter the genetic mixture.
24 So now the cell is transformed into a new cell line
25 which is now uncontrolled and in growth. The other

1 mechanism, being enzymatic or a tissue injury pathway
2 as a result of chronic recurrent tissue, might occur
3 from trichloroethylene or other chlorinated hydrocarbon
4 solvents which produce various organ injury such as
5 injury to the liver. The chronic recurrent injury
6 over a period of many years into the repair process by
7 chance alone, there will be spontaneous mutations
8 which will occur which will again transform cells
9 into a new cell line which now become uncontrolled
10 in their growth. So both of these result in
11 transformation of cells to a new cell line." It's
12 says lining, but I think it should be line. "The
13 hazard with the genotoxic organic pathway is only
14 a cell, a single cell, to transform the DNA."
15
16
17
18
19
20
21
22
23
24
25

9-1

1 Q. Is that statement consistent or inconsistent
2 with testimony you have given here today?

3 A. That statement is consistent with the testimony
4 I have given here today.

5 Q. Turn if you will to page 50, at the bottom of
6 the page, and Mr. Walsh queries you as follows:

7 "Q. With respect to chloroform, can you advise
8 the Court as to its toxic properties?"

9 Would you give me your answer to that, please?

10 A. (Reading) "A. Chloroform is an -- it says
11 UP -- I don't know what that means -- chloroform is
12 an up as opposed to the ethane. It is a single carbon
13 atom, and chloroform has been around for a long period
14 of time. Chloroform is a very potential anesthetic.
15 It has very potent properties to depress the central
16 nervous system. It was actually used for an extensive
17 period of time as an anesthetic agent. Most recently,
18 and the reason it was discarded as an anesthetic
19 compound is because it sensitizes the heart tissue
20 to the compounds that are known as catecholamines,
21 c-a-t-h-e-p-o-l-m-i-n-e-s and the cadmium, c-a-d-m-i-u-m,
22 are the materials that cause the heart to beat faster,
23 and chloroform sensitizes the heart and those compounds
24 and causes an arrhythmia. It results in very sudden
25 death as a result of the exposure to the vapors of

9-2

1 chloroform, is one of the reasons for abandoning it
2 as an anesthetic."

3 Q. (Reading) "Q. Because it will fibrillate the
4 heart?

5 A. (Reading) "A. Cause fibrillation and cause
6 immediate death. It is also toxic to various organs.
7 It produces --"

8 Q. (Interposing) I expect that is hepatotoxic.

9 A. (Continuing to read) "-- hepatotoxic"--
10 I think that sentence should be "It produces hepatotoxicity.
11 It produces hepatotoxic injury to the liver resulting
12 in destruction of liver cells; resulting in extensive
13 liver damage. It also damages the kidneys and it is
14 a recognized carcinogenic as well as being a teratogen."

15 Q. I will ask you this, sir, with regard to that
16 statement: Would it take a large or small dose of
17 chloroform to create extensive liver damage?

18 A. It would take a very large dose.

19 Q. On the order of how many parts per billion or
20 million, sir?

21 A. It would take hundreds of thousands of parts
22 per million.

23 Q. Would it take a large or small dose to damage
24 the kidneys?

25 A. It would be the same. It would take a very

9-3

1 large dose.

2 Q. I will ask you to turn to page 60 of the
3 transcript if you will, please. Mr. Walsh asked you
4 the following question, bottom of the page:

5 "Q. Dealing with the actual water quality
6 criterion as they affect human beings, does the water
7 quality criterion itself indicate the water is safe
8 to drink?"

9 Now, your answer.

10 A. (Reading) "A. No; the contrary. For those
11 substances which are known carcinogens or suspect
12 carcinogens there is a statement that no level is
13 safe. But assuming a certain level of contamination
14 the increased risk for cancer would be at a certain
15 level, assuming consumption of the water at that
16 level of contamination."

17 Q. (Reading) "Q. You actually deal with the
18 concept of the water quality criterion at paragraph
19 35 of your affidavit, 175 in evidence, do you not,
20 Dr. Harbison?"

21 A. (Reading) "A. That's correct."

22 Q. (Reading) "Q. I wonder if you could advise
23 the Court and counsel what the risk factor is based
24 upon and how U. S. EPA has come up with the so-called
25 water quality criterion?"

9-4

1 A. (Reading) "A. The risk factor is based upon
2 an extrapolation of animal data from a high dose to
3 a low dose. Through that extrapolation process the
4 risk factor is determined that based upon a certain
5 level of exposure there will be a likelihood of
6 one or more cancers occurring for certain numbers
7 of population or for a certain number of people who
8 would be exposed to that particular contaminant in
9 the drinking water."

10 Q. Now, I am asking you this question exclusive
11 of the record to which we are referring, and by the
12 way, that record, for our transcript, is Exhibit 505.

13 Is that a lifetime exposure?

14 A. That is a lifetime exposure.

15 Q. Doctor, I have just one more area to query
16 you about. If you will turn to page 78 of the cross
17 examination. Mr. Gladden asked you this question:

18 "Q. You have testified at length about the
19 types of chemicals and their results on the human
20 cells. In fact, that some cause cancer mutations,
21 et cetera. Do we get into a problem of how much
22 dosage causes or has the kind of effects that you
23 have testified to on the cells?"

24 And your answer?

25 A. (Reading) "Yes."

9-5

1 Q. (Reading) "Q. What kind of dosages are we
2 talking about?"

3 A. (Reading) "A. For which effect?"

4 Q. (Reading) "Q. Well, let's take the first one.
5 For the cancerous things."

6 A. (Reading) "A. For the cancer effect depending
7 on whether it is a genetic pathway or a genetic action
8 orepigenetic pathway, probably as we have already
9 pointed out, maybe only one molecule. That doesn't
10 seem very probable, but certainly that is a workable
11 hypothesis. For the recurrent tissue injury we would
12 have to have enough exposure to provide or to produce
13 some sort of organ injury. So, for example, trichloro-
14 ethane or some of the smaller molecular weight
15 chlorinated hydrocarbons, it would be a much larger
16 dose."

17 Q. (Reading) "Q. Does the dosage also affect
18 whether the results on the cells are acute or chronic
19 in nature?"

20 A. (Reading) "A. It can, yes."

21 Q. (Reading) "Q. I notice that the water policy
22 criteria talked about a lifetime situation. What does
23 that mean?"

24 A. (Reading) "A. It means ingestion of that
25 material for the lifetime of the individual."

6
1 Q. (Reading) "Q. Well, I am a layman. I have
2 a little trouble understanding that. Are we saying
3 that if a person throughout his lifetime -- we take
4 the normal life -- what, sixty years, seventy years,
5 something like that?"

6 A. (Reading) "A. Yes."

7 Q. (Reading) "Q. Is that what is done to
8 create this standard, ingest the chemical involved
9 for a lifetime, then he is exposed to the risk of one
10 in a million or whatever the test comes out to be?"

11 A. (Reading) "A. That is correct."

12 Q. Dr. Harbison, were there certain wells that
13 were involved in this lawsuit?

14 A. Yes.

15 Q. Before we get to that, there was some reference
16 to your putting into evidence in that transcript a
17 flow chart or something that described the genotoxicity
18 route as opposed to the other route, the recurrent
19 injury route.

20 A. Yes.

21 Q. Do you remember what that looked like?

22 A. Yes, I do.

23 Q. Do you have one of those with you?

24 A. Yes, sir, I do.

25 Q. And what is it contained?

9-7

1 A. That chart is contained in the book that we
2 has put together for the U.S. EPA, entitled "Toxicological
3 Evaluations, Risk Assessment and Safety Determinations
4 for Chemical Exposures."

5 Q. Do you have more than one copy of that book?

6 A. No, sir. I only have the one.

7 Q. Would you turn to wherever that flow chart is
8 located, if you will, please?

9 A. That flow chart is located between page 55
10 and 56.

11 Q. Would you hand it to me so I may show it to
12 opposing counsel first.

13 A. All right, sir.

14 MR. GENTRY: With the Court's permission,
15 may I hand this particular chart to the court?

16 THE COURT: I see what it looks like.
17 It looks awfully complicated. Maybe he can just
18 describe what it is.

19 MR. GENTRY: All right, Your Honor.

20 Q. Tell me what that chart shows, if you will,
21 please, Dr. Harbison?

22 A. Well, the chart shows that a substance is
23 metabolized or changed from a parent compound to a
24 metabolite, and that metabolite can result in tissue
25 injury or produce cancer as a result of an epigenetic

-8

1 pathway, or it can bind to DNA directly and cause
2 cancer by genotoxic pathway, and it goes on to describe
3 the various kinds of damage that would be produced
4 as a result of that metabolic transformation.

5 Q. You referred to tissue damage as far as that
6 chart is concerned. Is that the same thing as cell
7 death?

8 A. Yes, it is.

9 Q. Does that chart describe the type of compounds
10 that you think carbon tetrachloride and chloroform are?

11 A. Yes, it does.

12 Q. What does it say about those two compounds?

13 A. Well, it --

14 Q. (Interposing) I know it doesn't refer to those
15 two compounds specifically. But what does it say
16 about them?

17 A. That the epigenetic pathway is the pathway
18 by which carbon tetrachloride and chloroform produce
19 recurrent cell damage and cell death and can result
20 over a prolonged period of time in the production
21 of cancer.

22 Q. Is that chart in any way contrary to your
23 testimony that you have given here today?

24 A. No, it is not.

25 MR. GENTRY: Would you make that entire

-9

1 volume an -- we seem to be putting in things
2 by books, Your Honor -- so I would just
3 standardize the procedure and ask the court
4 to admit the book as Exhibit 506, with the
5 understanding that that chart is contained
6 between pages 55 and 56.

7 THE COURT: All right.

8 Q. (By Mr. Gentry) Would you make that an
9 exhibit for identification?

10 (The document above-referred to was
11 marked Exhibit 506, for identification.)

12 Q. (By Mr. Gentry) Just so I understand, I
13 will ask you again -- what is that book?

14 A. This is the book that we have prepared which
15 is entitled "Toxicological Evaluation: Risk Assessments
16 and Safety Determinations for Chemical Exposures."

17 It was prepared for the United States Environ-
18 mental Protection Agency for teaching this course
19 to its people and the Department of Public Health
20 persons in the southeast.

21 Q. Anywhere in that book do you advise the
22 EPA to use a percentage as a risk assessment?

23 A. No, sir.

24 Q. Let me ask you to turn your attention for a
25 moment to Exhibit 504, and let's just go to the first

9-10 1 well on page 14 of 504.

2 A. Yes.

3 Q. I notice there are inorganic compounds and
4 organic compounds in that well?

5 A. That's correct.

6 Q. Of the organic compounds, am I correct most
7 of them are chlorinated hydrocarbons, but not all?

8 A. That is correct.

9 Q. How many parts per billion of chlorinated
10 hydrocarbon do you have in that first well?

11 A. Well, I roughly added it up, and it is about
12 140,000 parts per billion.

13 Q. Of all chlorinated hydrocarbons?

14 A. That is correct.

15 Q. Of which chloroform represents how many
16 parts per billion?

17 A. 68 parts per billion.

18 Q. Now, you are not counting the inorganics
19 in there, are you, sir?

20 A. No, I am not.

21 Q. What is the largest combination of chloroform
22 and carbon tetrachloride in the worst year on Exhibit
23 375?

24 A. Well, it looks to be about 10,300, and I
25 would say 40 or 50 -- 10,350 parts per billion.

Q. Of --

A. Of chlorinated hydrocarbons.

Q. When you look at the organic compounds in well No. 1, are there some or many heavy molecular weight chlorinated hydrocarbons, I should have said few or many.

A. There are -- compared to carbon tetrachloride and chloroform, there are many which have a higher molecular weight.

Q. Turn over to page 15, and let's look at the inorganics on well No. 2 just for a minute.

I notice they have arsenic, 31 parts per billion there. Is that a known human carcinogen?

A. Yes, sir. Arsenic is a known human regulated cancer-causing agent.

Q. Are there any other of those heavy metals that are known regulated human carcinogens?

A. I am not sure. Cadmium, maybe. I am not really for sure about that. I don't think it is on the list of known.

Q. What was the United States asking as it related to these wells, what was their position as it related to these wells?

A. My understanding of the position of the United States Department of Justice is that it was asking for

1 a new water supply to these people who had contaminated
2 wells and was further asking for some relief to the
3 possible intake of these materials into the Atlantic
4 City water supply, and that relief was in the form
5 of moving the water intake for the City of Atlantic
6 City to some other place such that it would not
7 take these materials into it.

8 Q. Were the people still ingesting the water
9 from those wells at that time?

10 A. To the best of my knowledge I believe they were.

11 Q. Doctor, in light of the cross examination,
12 I am going to ask you one question, one more question.
13 What is the scientific reason for your testimony that
14 there is no risk of cancer in these people who ingested
15 the waters as we see them in Exhibit 375?

16 A. The scientific basis for my testimony considers
17 the mechanism of action of carbon tetrachloride and
18 chloroform; that is what we know, both about its
19 metabolism and its interaction with cells and parts of
20 cells. Both carbon tetrachloride and chloroform
21 are not converted to metabolites which interact with
22 DNA. They could not possible form substances which
23 interact with DNA to lead to initiation of cancer,
24 and, further, based upon our occupational experience
25 with carbon tetrachloride, and chloroform, which has a

1 long history, there is no evidence that these two substance
2 have resulted in an increased incidence of cancer,
3 and, further, based upon our extensive experience with
4 the use of these materials as therapeutic agent
5 in the pharmaceutical sciences, again there is a long
6 continued history and safe use of these materials
7 for the treatment of a variety of diseases. So it is
8 based upon my knowledge of the mechanism of action
9 of these materials and also based upon their
10 past incidence of use.

11 MR. GENTRY: Thank you, Dr. Harbison,
12 that is all.

13
14 RECROSS EXAMINATION
15 BY MR. GILREATH:

16 Q. Doctor, looking at Exhibit 13, is toluene
17 a genetic or epigenetic carcinogen?

18 A. I don't believe that there is very much
19 evidence regarding the carcinogenicity of toluene.
20 I couldn't answer that question.

21
22
23
24
25
end

10-1

1 Q How about benzene?

2 A Benzene. There is certainly evidence that
3 benzene can be metabolized to a metabolite which could
4 bind to DNA. It can be metabolized to an epoxide, it
5 certainly has that potential.

6 Q And naphthalene?

7 A Naphthalene, my response would be similar to
8 that for benzene. Certainly has the molecular
9 configuration whereby it could be biotransformed to
10 a compound that could bind.

11 Q All right. That would make them, then,
12 under your definition, a genetic carcinogen as opposed
13 to an epigenetic, is that right?

14 A Yes, sir. My opinion about that would be
15 that those would be much more likely to be genotoxic
16 agents.

17 Q All right. Now, if you take a genetic
18 carcinogen such as those two, then you have the
19 potential for what you call the one-hit mechanism,
20 don't you?

21 A Well, I don't call it the one-hit mechanism.
22 There certainly is a hypothesis that suggests that.
23 A single chemical can interact with a single strand
24 of DNA to cause transformation of a cell, and certainly
25 naphthalene and benzene, based upon their molecular

1 configuration, could have that potential.

2 Q Look on Page 32 of your testimony at Line 7,
3 the question:

4 "This sometimes" --

5 A I'm sorry, I haven't found it yet.

6 Q Okay. I'm sorry.

7 A Page 32?

8 Q Yes.

9 A Yes.

10 Q "This sometimes called the one-hit hypothesis?

11 ANSWER: That is correct."

12 A Yes, sir.

13 Q Now, the one-hit hypothesis is outlined
14 in your affidavit on Page 4, is it not, under Number
15 11?

16 A Yes, sir. It says in theory, that's correct.

17 Q That's what you are talking about there is the
18 one-hit hypothesis. Would you read that, please?

19 A "In theory, it might take only a single
20 molecule of chemical to produce a mutation in the DNA
21 of a body cell. A single chemical molecule in a
22 liter of water would have an extremely small possibility
23 of causing such change, but when a chemical
24 contaminant reaches the level of detectability it is
25 present in a liter of water in a number of hundreds of

1 trillions or quadrillions of molecules, ten to the
2 fourteen or ten to the fifteen molecules. What seems
3 an insignificant exposure, tens of parts per billion,
4 for example, is in reality an occasion for an
5 enormous number of damaging encounters between a chemical
6 carcinogen and its DNA target in body cells. It is
7 in this way that very small exposures can lead to
8 damage."

9 Q There you are talking about the concept of
10 causing cancer without first causing injury?

11 A That is correct, that is the direct binding
12 of the substance to the DNA.

13 Q May I see your green book there for a moment?

14 All right, looking at Exhibit 506, on the left
15 is your epigenetic mechanism, is that right?

16 A Yes, sir.

17 Q All right. Now, in your epigenetic mechanism
18 you assume that there is some repair and regeneration?

19 A Yes.

20 Q All right. Now -- and that there is no
21 immunosuppression?

22 A That is correct.

23 Q Now, this thesis that you are advocating there,
24 then -- and I'm reading from the book on carbon
25 tetrachloride and other -- chloroform and carbon tetra --

1 the National Research Council book. Is that the one
2 you read from earlier?

3 A Yes, it is.

4 Q All right. Let me show it. On Page 167 --
5 187, excuse me, there where it says, "The threshold
6 model" in the third paragraph down.

7 A Yes.

8 Q "The threshold model assumes some critical
9 level of exposure below which the carcinogenic process
10 will not be" -- is that word initiated?

11 A Yes.

12 Q "The arguments in support of no effect levels
13 generally center around the concept of proper
14 detoxification and adequate repair system, including
15 DNA repair and immunosuppression."

16 So if those -- that thesis assumes that there
17 is an adequate repair system, and so forth, is that
18 right?

19 A That is correct.

20 MR. GILREATH: That's all we have.

21 MR. GENTRY: First, Your Honor, may I
22 inquire of Mr. Gilreath if that's our book
23 that's in possession of the witness?

24 MR. GILREATH: Yes.

25 MR. GENTRY: I have just two questions,

1 Your Honor.

2 REDIRECT EXAMINATION
3 BY MR. GENTRY:

4 Q Doctor, I will show you Exhibit 357, which is a
5 run down --

6 MR. GENTRY: If the Court please.

7 I'm sorry.

8 THE COURT: Yes, sir, go right ahead.

9 BY MR. GENTRY:

10 Q -- which is a run down of the Sterling and
11 Johnson wells made by ERM, look at 10 and 12,
12 and tell me if you can find benzene in any amount
13 in that particular exhibit in either the Johnson
14 or Sterling well?

15 A No, I do not find it.

16 Q Do you find naphthalene?

17 A In the Sterling well?

18 Q Yes.

19 A Yes.

20 Q All right. Do you find any reading above your
21 reference ten parts per billion?

22 A No, I do not.

23 Q What's the highest?

24 A The highest is six point three parts per billion.

25 Q Are there any nondetectables there?

1 A Yes, there are.

2 Q Turn over to the Johnson well, if you will,
3 please.

4 A Yes, I find naphthalene.

5 Q Any above your reference ten parts per billion?

6 A No.

7 Q What's the highest?

8 A The highest is two point seven parts per billion.

9 Q Any nondetectables?

10 A Yes, there are.

11 MR. GENTRY: All right, thank you.
12 That's all.

13 MR. GILREATH: That's all we have.

14 THE COURT: All right. You may step
15 down, please.

16 MR. GENTRY: If the Court pleases, may
17 Dr. Harbison be excused?

18 THE COURT: Any objection, Mr. Gilreath?

19 MR. GILREATH: No, Your Honor.

20 THE COURT: All right.

21 (Witness excused.)

22 MR. GENTRY: If the Court pleases.

23 THE COURT: Yes, sir.

24 MR. GENTRY: May it be allowed for Mr.
25 Hanson to leave the table? He's going to try

1 to take Dr. Harbison to the plane.

2 THE COURT: All right, sir.

3 MR. GENTRY: Your Honor, we have a couple
4 of housekeeping matters which may or may not
5 be mooted by some previous statement concerning
6 how -- Exhibits.

7 Excuse me, Your Honor. It seems that I
8 have to give the keys to someone.

9 THE COURT: All right.

10 Mr. Wharton.

11 (Whereupon, an off-the-record
12 discussion was had.)

13 THE COURT: All right, Mr. Gentry,
14 go right ahead.

15 MR. GENTRY: Your Honor, there is an
16 exhibit 388 which contains a stipulation between
17 the parties. That is the rather bulky
18 exhibit that contained the various headlines
19 from newspapers.

20 THE COURT: Yes.

21 MR. GENTRY: We have not read the
22 stipulation into evidence. This was accepted
23 into evidence and the better part of valor
24 prompts us to ask the Court if the stipulation
25 and the documents contained therein are indeed

1 in evidence for the purpose for which they
2 were stipulated.

3 THE COURT: It is for the Court, because
4 if you were to undertake to read that I would
5 certainly help you find the solution to the
6 problem.

7 MR. GENTRY: Thank you, Your Honor.
8 That was a housecleaning job we wanted to make
9 sure was finished.

10 THE COURT: Yes.

11 MR. GENTRY: We have one other item to which
12 the Court can direct its attention and, under
13 the Rules of Evidence as we understand them,
14 take judicial notice. It is a portion of the
15 Federal Register dated January 4, 1983,
16 which announces a partial administrative stay
17 with reference to the identification and
18 classification and regulation of potential
19 occupational carcinogens. That was the result
20 of the colloquy -- I mean we proffered this as
21 a result of the colloquy the other day as to
22 whether or not there was -- whether it had been
23 cancelled or whether it had been put in some
24 kind of limbo, and we find that the proper
25 words are partial stay.

1 And we would proffer this for the Court's
2 perusal.

3 THE COURT: All right.

4 Any objection, Mr. Gilreath?

5 MR. GILREATH: No, Your Honor.

6 THE COURT: All right.

7 MR. GENTRY: We would like to mark it
8 as an exhibit.

9 THE CLERK: It will be Number 507.

10 (Whereupon, the above-mentioned
11 document was marked Exhibit Number 507
12 to the testimony of the witness and will be
13 found among the exhibits hereto.)

14 MR. GENTRY: I'm about to utter words that
15 I suspect will be of great relief to the Court.

16 That completes the defendant's defense.

17 THE COURT: All right, sir. It is a joy
18 to hear those words. Of course, there are
19 words that could be more joyful.

20 But I had better be serious on the record,
21 Mr. Gentry. The Court understands.

22 Mr. Gilreath, it's up to you to say
23 something.

24 MR. GILREATH: We are ready to go forward
25 with our rebuttal.

1 THE COURT: All right. I take it there
2 are no motions or anything at this point?

3 MR. GENTRY: Well, Your Honor, there are
4 some motions that we would like to make. I
5 was almost referring then to make a suggestion
6 to the Court that perhaps as it relates to the
7 proposed rebuttal proof we should have
8 parameters. I can visualize a retrying of the
9 plaintiffs' case if true rebuttal is not
10 adhered to, and I don't know whether the Court
11 has really --

12 THE COURT: Mr. Gentry, a week or so ago
13 you all heard me tell a fine man standing there
14 that the Court could not presume that the
15 Internal Revenue Service would not follow the
16 law. Well, I certainly can't presume that
17 able lawyers such as Mr. Gilreath and Mr. Wilder
18 and Mr. Garrety will not follow the law and the
19 rules that apply any more than I could presume
20 that you or Mr. Spragins or Mr. Mitchell would
21 not follow the law.

22 So I think the Court has to assume that
23 until the Court's assumptions are demonstrated
24 to be misplaced assumptions.

25 MR. GENTRY: The simile is well taken,

1 Your Honor.

2 THE COURT: Thank you.

3 MR. GENTRY: I understand --

4 THE COURT: The other thing, it seems
5 to me, is that it might be helpful for us to
6 go ahead and complete the proof in this case.
7 Then if it becomes necessary down the road,
8 we can take up really any motions that might be
9 necessary, and you have that flexibility where
10 it's a nonjury trial.

11 MR. GENTRY: Very well, Your Honor.
12 With that suggestion from the Court, we will
13 not proffer our motions at this time.

14 THE COURT: All right, sir. And I think
15 the Court ought to state on the record that
16 neither side waives anything --

17 MR. GENTRY: Thank you, Your Honor.

18 THE COURT: -- in accepting the Court's
19 suggestion.

20 MR. WILDER: Your Honor, I have one
21 housekeeping matter too. When I was reviewing
22 the transcript last week prior to Mr. Wade's
23 testimony, I was going back and looking at
24 Exhibit 276 that had been introduced for --
25 I thought as an exhibit introduced into the

1 record, but possibly there was a caveat
2 put on the introduction of it by Mr. Spragins.
3 This is the real estate notebook of Mr. Murdaugh's,
4 and I believe the caveat was that if he saw
5 any objection he would make it. If not,
6 it would go into evidence. But I did not
7 officially move it into evidence after Mr.
8 Murdaugh's testimony and I would like to do
9 that at this time.

10 THE COURT: All right. Is there any
11 objection at this point, Mr. Gentry?

12 MR. GENTRY: I will defer to MR. Spragins,
13 if the Court please.

14 THE COURT: All right, sir.

15 MR. SPRAGINS: I haven't thought about it
16 for several months, Your Honor. My recollection
17 is that I didn't have any objections.
18 I will tell you for sure in the morning.

19 MR. WILDER: Very well, Your Honor.

20 THE COURT: Well, suppose we go ahead
21 and admit it subject to whatever objections,
22 if any, Mr. Spragins might come up with.

23 MR. SPRAGINS: That is all right.

24 MR. WILDER: Thank you.

25 (Whereupon, the above-referred to

1 document was marked Exhibit Number 276
2 to the testimony of the witness and same
3 will be found among the exhibits hereto.)

4 MR. GARRETY: If the Court please, call
5 Dr. Scott Clark.

6 THE COURT: All right, sir.

7 Do you gentlemen want Dr. Clark sworn
8 again? I don't think it's necessary.

9 MR. GENTRY: No necessity for that, Your
10 Honor.

11 THE COURT: All right, sir.
12
13
14
15
16
17
18
19
20
21
22
23
24
25